GENOME-WIDE SEARCH FOR NOVEL CANCER GENES IN SPORADIC AND FAMILIAL COLORECTAL CANCERS by THEAN LAI FUN
 i 
GENOME-WIDE SEARCH FOR NOVEL CANCER 








THEAN LAI FUN 






A THESIS SUBMITTED FOR  







SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH 
 














I hereby declare that this thesis is my original work and it has been written by me in 
its entirety. I have duly acknowledged all the sources of information which have been 
used in the thesis. 
 






                               ------------------------------------------------------ 
   THEAN LAI FUN 
 









I would like to take this opportunity to express my gratitude towards several persons 
for the support and guidance that I received throughout my PhD candidature journey.  
 
First and foremost, my supervisor and director of the laboratory, Associate Professor 
Dr Cheah Peh Yean, for her guidance and support throughout my candidature; for her 
to understand my juggling between PhD, career and motherhood and my absence from 
the office while attending courses in NUS. 
 
Next, my co-supervisor as well as thesis advisor, Professor Dr Teo Yik Ying, for his 
guidance, encouragement and invaluable input in teaching me the theories behind the 
statistics as well as introduced me to his research fellow, Dr Chen Peng to assist me in 
imputation. 
 
Subsequently, my thesis advisor, Professor Dr Koh Woon Puay for her suggestions and 
support; 
 
My lab members and friends at SGH, Michelle Lo, Elya and Wei Lin for the technical 
help and support, for the joys and laughter that we shared; and  
 
My family, my beloved parents, siblings and husband for their unconditional love and 
















Table of Contents 
Acknowledgements ...................................................................................................... iii 
Table of Contents .......................................................................................................... iv 
Summary viii 
List of Figures ................................................................................................................ x 
List of Tables ............................................................................................................. xiii 
List of Symbols and Abbreviations............................................................................. xiv 
Chapter 1 Introduction ................................................................................................. 1 
1.1 Colorectal Cancer ................................................................................................ 1 
1.1.1 Colorectal Cancer Incidence ..................................................................... 1 
1.1.2 Colorectal Cancer and Heredity ............................................................... 2 
1.1.3 Molecular Classification of Colorectal Cancer ...................................... 15 
1.2 Human Genome Variations ............................................................................... 18 
1.2.1 Single Nucleotide Polymorphism (SNP) ................................................ 18 
1.2.2 Copy Number Variation (CNV) ............................................................. 19 
1.3 Decoding the Human Genome .......................................................................... 20 
1.3.1 The Human Genome Project, International HapMap Project and 1000 
Genomes Project ..................................................................................... 20 
1.3.2 Cancer Genome Analyses ....................................................................... 22 
1.3.3 Encyclopedia of DNA Elements (ENCODE) ......................................... 24 
1.3.4 The Singapore Genome Variation Project (SGVP) ................................ 24 
1.4 Genome-wide Association Study (GWAS) ....................................................... 25 
1.4.1 GWAS and Colorectal Cancer ................................................................ 27 
1.4.2 GWAS and ethnicity ............................................................................... 29 
1.4.3 GWAS and imputation ........................................................................... 32 
Chapter 2 Aims........................................................................................................... 34 
Chapter 3 Materials and Methods .............................................................................. 36 
3.1 Patients and Sample collection .......................................................................... 36 
3.1.1 GWAS samples ....................................................................................... 36 
3.1.2 Familial CRC samples ............................................................................ 37 
3.2 Affymetrix Genome-Wide Human SNP Array 6.0 (SNP 6 Array) ................... 38 
3.2.1 Restriction Enzyme Digestion and Adaptor Ligation ............................. 39 
3.2.2 Polymerase Chain Reaction (PCR) of Ligated Products ........................ 40 
3.2.3 PCR Product Purification ....................................................................... 41 
3.2.4 Quantitation, Fragmentation and Labelling ............................................ 42 
 v 
3.2.5 Target Hybridization ............................................................................... 43 
3.2.6 Washing, Staining and Scanning Arrays ................................................ 44 
3.2.7 Data Quality Evaluation with Genotyping Console 3.0 Software .......... 44 
3.3 SNP Genotyping and Optimized CN Assays .................................................... 45 
3.3.1 Taqman SNP Genotyping ....................................................................... 45 
3.3.2 Taqman Copy Number Assay ................................................................. 48 
3.3.3 Qiagen Multicopy Reference (MRef) ..................................................... 49 
3.4 GWAS Data Analysis ........................................................................................ 51 
3.4.1 Golden Helix SNP and Variation Suite (SVS) ....................................... 51 
3.4.2 Copy Number and Expression Profile Analysis ..................................... 57 
3.4.3 Statistical Package for Social Science (SPSS) ....................................... 57 
3.4.4 Ingenuity Pathway Analysis (IPA) ......................................................... 57 
3.5 Familial CRC Data Analysis ............................................................................. 58 
3.5.1 Microsatellite instability assay ............................................................... 58 
3.5.2 Partek Genomic Suite (PGS) .................................................................. 58 
3.5.3 Data mining on the confirmed deleted region ........................................ 59 
3.6 Imputation ......................................................................................................... 60 
3.7 Fluidigm SNPtype Assay on 192.24 Integrated Fluidic Circuits (IFCs)  Array ... 
  ........................................................................................................................... 62 
3.8 Real time RT-PCR assay ................................................................................... 65 
3.9 Long-range Polymerase Chain Reaction ........................................................... 67 
Chapter 4 Data Quality Checks for GWAS Dataset .................................................. 68 
4.1 SNP Data ........................................................................................................... 68 
4.2 CN data .............................................................................................................. 77 
4.3 Conclusions ....................................................................................................... 84 
Chapter 5 Association of Caucasian-Identified Variants with Colorectal Cancer Risk 
in Singapore Chinese ................................................................................ 85 
5.1 Aim of the Study ............................................................................................... 85 
 5.1.1     Sample size used in the study ................................................................... 85 
5.2 Background ....................................................................................................... 85 
5.3 Results and Discussion ...................................................................................... 87 
5.4 Conclusions ....................................................................................................... 97 
Chapter 6 Genome-wide SNP Association Study ...................................................... 98 
6.1 Aim of the study ................................................................................................ 98 
 6.1.1     Sample size used in the study ................................................................... 98 
 vi 
6.2 Background ....................................................................................................... 98 
6.3 Results and Discussion ...................................................................................... 99 
6.3.1 CRC GWAS Panel .................................................................................. 99 
6.3.2 CRC GWAS and SP2 Panels ................................................................ 105 
6.3.3 Imputed data of CRC GWAS, SP2 1M and 1000 Genome .................. 113 
6.3.4 CRC GWAS Haplotype Association Test ............................................ 116 
6.4 Conclusions ..................................................................................................... 122 
Chapter 7 Genome-wide Association Study Identified Common and Rare Copy 
Number Variants associated with Sporadic Colorectal Cancer Risk ...... 123 
7.1 Aim of the study .............................................................................................. 123 
 7.1.1     Sample size used in the study ................................................................. 123 
7.2 Background ..................................................................................................... 123 
7.3 Results and Discussion .................................................................................... 124 
7.3.1 CNV burden analysis for multivariate segmenting in cases and controls .. 
 .............................................................................................................. 124 
7.3.2 CNV association testing after multivariate segmentation .................... 125 
7.3.3 Rare CNV association testing after univariate segmentation ............... 127 
7.3.4 Validation of CNV loci by optimized copy number assay ................... 128 
7.3.5 Interrogating gene expression profiles by CN status of CNV loci ....... 129 
7.4 Conclusions ..................................................................................................... 135 
Chapter 8 Chromosome 19q13 Disruption Alters Expression of CYP2A7, MIA and 
MIA-RAB4B lncRNA and Contributes to FAP-like phenotype in APC 
Mutation-negative Familial Colorectal Cancer Patients ......................... 136 
8.1 Aim of the Study ............................................................................................. 136 
8.1.1     Sample size used in the study ................................................................. 136 
8.2 Background ..................................................................................................... 136 
8.3 Results and Discussion .................................................................................... 137 
8.3.1 Identification of APC-mutation negative familial CRC patients .......... 137 
8.3.2 Prediction of 5 deletions shared by the two affected siblings .............. 138 
8.3.3 Validation of the genomic deletion at chromosome 3q28 and 19q13 .. 139 
8.3.4 In silico analysis of the 1Mb region encompassing the 32kb deleted 
region .................................................................................................... 142 
8.3.5 Expression of CYP2A7 and TGFβ1 ...................................................... 145 
8.3.6 Expression of MIA, lncRNAs and EGLN2 ........................................... 146 
8.3.7 Expression of a subset of miR-24 regulated genes ............................... 147 
8.4 Conclusions ..................................................................................................... 154 
 vii 
Chapter 9 Overall Conclusions and Future Study .................................................... 155 





Colorectal cancer (CRC) is the third most frequent cancer worldwide. In Singapore, it 
is the most frequent cancer and second leading cause of cancer mortality. About 80% 
of CRC are classified as sporadic with no family history. Another 10% are familial 
syndromes caused by mutations in well characterized genes, while the aetiology of the 
remaining 10% is currently unclear. Similarly, twin studies have estimated that heredity 
contributed 35% to the aetiology of sporadic CRC but the single nucleotide 
polymorphisms (SNP) and structural or copy number variants (CNV) associated with 
sporadic CRC are not yet clearly defined. 
 
With the availability of high density SNP arrays, genome-wide association study 
(GWAS) allows researchers to search for the association of common genetic variants 
with disease by comparing the allele frequencies of variants between cases and controls.  
 
In this study, we performed a GWAS on 1,000 stringently defined cases and 1,000 age-, 
gender- and ethnicity-matched healthy controls using the SNP6 platform to identify risk 
loci for sporadic CRC in Singapore Chinese (SCH).  
 
Currently, about twenty Caucasian-identified SNPs were reported to be associated with 
CRC risk. Nevertheless, different populations have different genetic structures, 
rendering replication in different populations a necessity. We investigated the effects 
of these risk variants in SCH. The first identified and most frequently replicated 
susceptibility loci for CRC risk in Caucasian population, rs6983267 at chr8q24.21, was 
found to show trend of association based on dominant model (OR=1.38, 95% CI 1.13-
1.60, Pdominant=0.042) in SCH. Only six out of the fourteen SNPs interrogated showed 
 ix 
evidence of association with CRC risk in SCH, indicating that unidentified potential 
variants associated with CRC risk are yet to be discovered.  
 
SNP association test, however, did not identify new SNP variant in SCH. Nevertheless, 
in collaboration with the Asian CRC Consortium, our dataset contributed to the 
identification of a new SMAD7 risk variant in East Asians. Further, imputed rs5275 
frequencies from our dataset contributed to the significant association with CRC risk in 
Singapore female patients. SMAD7 is a gene in the TGF pathway and rs5275 is a SNP 
at 3’ end of Cyclooxygenase-2 gene previously implicated in colorectal tumorigenesis.  
 
Subsequently, copy number (CN) association test identified a rare CNV at chr14q11 
encompassing CHD8 (OR=1.92, 95% CI 1.59-2.32) and two common CNVs at 
chr3q13.12 (OR=1.54, 95% CI 1.33-1.77) encompassing CD47 and chr12p12.3 
(OR=1.69, 95% CI 1.41-2.01) consisting RERG and ARHGDIB significantly associated 
with sporadic CRC in SCH. CHD8 is a chromatin modifier in the Wnt signalling 
pathway while RERG and ARHGDIB are linked to proliferation and tumorigenic 
potential and metastasis. Genome-wide expression studies based on a subset of tumours 
revealed that CN loss in rare CNV perturbed more genes compared to common CNV. 
 
Finally, using genome-wide data from controls, we searched for novel causative genes 
in familial CRC patients with attenuated polyposis and undetectable mutations in 
known tumor-suppressors. The results implied that a chr19q13 genomic deletion caused 
chromatin disruption and perturbed expression of CYP2A7, MIA and MIA-RAB4B 
IncRNA, possibly contributing to tumorigenesis via both epigenetic and genetic 
mechanisms in these patients.  
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Chapter 1 Introduction 
 
1.1 Colorectal Cancer 
Colorectal cancer (CRC) is a form of cancer that develops in colon or rectum due to 
abnormal cell growth. It may start as small polyps and eventually, undergo malignant 
transformation and progress into invasive colorectal tumours. However, not all polyps 
are cancerous. Only less than 10% of the most common kind of polyp namely 
adenomatous polyp or adenoma will develop into cancer (Risio, 2010). Studies have 
showed that the probability of an advanced or large adenoma evolving into cancer is 
higher compared to small polyps that mostly remain stable or regress (Pickhardt et al., 
2013). Nevertheless, once cancer develops in the inner lining of the colon, it can 
penetrate the wall of either the colon or rectum followed by spreading via the blood and 
lymph vessels. Hence, cancer spreads into the nearby lymph nodes while blood vessels 
carry the cancerous cells to other distant parts of the body and this is called metastasis.  
 
1.1.1 Colorectal Cancer Incidence 
According to the World Health Organization (WHO), cancer contributes to the highest 
mortality rate worldwide. CRC is the third most common cancer worldwide in 2012 
(for both male and female) with 1.4 million cases being diagnosed that accounted for 
10% of overall cancers reported and the fourth most common cause of cancer death 
(694 000 deaths) (Ferlay et al., 2015). In Singapore, CRC was the most frequent cancer 
among the male resident population and second in females in the year 2010 to 2014 
with a total of 9324 new cases reported (Lee et al., 2015). This trend applied to the 
overall population as well as to the Chinese ethnic group. The age-standardized 
incidence rate was reported to be the highest in the Chinese compared to the Malay and 
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Indian ethnic groups. CRC mortality rate was ranked second in males with lung cancer 
contributing to the highest mortality rate. In females, CRC incidence ranked third after 
breast and lung cancer.  
 
1.1.2 Colorectal Cancer and Heredity 
Overall, CRC can be classified as inherited or non-inherited (Figure 1). About 80% of 
the CRC cases diagnosed are classified as sporadic CRC or non-inherited.  
 
 
Figure 1: Genetic architecture of known CRC genetic susceptibility loci. Adapted 
from Genetic architecture of colorectal cancer, by Peters, U. et al, 2013, 
Gut, 64, p. 1623. 
 
Twin studies attributed environmental factors as the major contributor of sporadic 
cancer with 35% of this CRC risk possibly be explained by heritable factors 
(Lichtenstein et al., 2000). About 10% of CRC cases are caused by well characterized 
mutations with high-penetrance hereditary. The remaining 10% are clinically defined 
as familial or inherited cases with unknown mechanism(s). This group of moderate or 
low-risk CRC cases might involve single genes alterations, i.e. common 
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polymorphisms with low-penetrance genes or gene combinations that may be 
influenced by environmental factors (Jasperson et al., 2010).  
 
Table 1 below shows a list of the hereditary colorectal cancer syndromes with the 
causative genes. A thorough understanding of the CRC susceptibility genes allows for 
the identification of high risk individuals and hence, improves the cancer surveillance 
and prevention strategies, followed by better diagnostic and therapeutic approaches. 
 
Table 1: Hereditary Colorectal Cancer and Genes 











































































FAP: Familial adenomatous polyposis; MAP: MUTYH-associated polyposis; PPAP: 
Polymerase-proofreading associated polyposis; NAP: NTHL1 associated polyposis; LS: 
Lynch syndrome; PJS: Peutz-Jedgers syndrome; JPS: Juvenile polyposis syndrome; CS: 
Cowden’s syndrome; AD: Autosomal dominant; AR: Autosomal recessive; TGFBR: 





1.1.2.1 Mendelian Colorectal Cancer Syndromes 
Familial Adenomatous Polyposis (FAP) 
Familial Adenomatous Polyposis (FAP) is the most common adenomatous polyposis 
syndrome and is one of the most well studied Mendelian CRC. It is caused by germline 
mutation in the adenomatous polyposis coli (APC) gene, a tumor suppressor gene 
located on 5q21 (van Es et al., 2001). Classical characteristic features of FAP include 
hundreds to thousands of colonic adenomatous polyps in the colon and rectum. If left 
untreated, one of these polyps will inevitably progress to cancer.  
 
The major role of APC is to regulate degradation of β-catenin through phosphorylation 
and localization (Nathke, 2004). Studies show that inactivation of APC hinders 
phosphorylation of β-catenin and leads to its accumulation. Subsequently, β-catenin 
translocates to the nucleus of the cell and activates the Wnt signalling pathway through 
LEF/TCF-mediated transcription (Yang et al., 2006). Due to the overexpression of 
growth-promoting genes from β-catenin-LEF/TCF interaction, FAP patients with APC 
mutation develop thousands of colonic polyps (Arce et al., 2006). As a result, 
perturbation of the APC gene affects cell differentiation, proliferation and migration, as 
well as apoptotic process (Sansom et al., 2004).  
 
As shown in figure 2, APC consists of 15 transcribed exons, and encodes a 312 KDa 
protein with the full length protein comprising 2843 amino acids (Galiatsatos and 




Figure 2: cDNA of APC with the protein motifs. Adapted from Familial 
Adenomatous Polyposis by Galiatsatos and Foulkes, 2006, Am J 
Gastroenterol, 101(2), p. 385-98. 
 
 
Reports have shown that most of the APC mutations lead to protein truncation or 
premature stop codons and result in non-functional or abnormal products. Most of these 
truncated products are due to nonsense mutations (30%), frameshift mutations (68%), 
or large deletions (2%) with the mutation hot spots located at codons 1061 and 1309 
(Beroud and Soussi, 1996). Somatic and germline mutations of the APC gene are found 
to show different distributions. Somatic mutations are mostly located on the mutation 
cluster region (MCR) while germline mutations are found throughout the first half of 
the coding region (Mori et al., 1993). Nevertheless, there are about 20-50% of the 
patients present with the FAP phenotype but with no APC mutation detected (Sieber et 
al., 2002; Michils et al., 2005; Galiatsatos and Foulkes, 2006). 
 
Besides the classical colonic defect, FAP patients may develop polyps in the upper 
gastrointestinal tract, extracolonic clinical manifestations such as congenital 
hypertrophy of retinal pigment epithelium (CHRPE), facial osteomas, sebaceous and 
epidermoid cysts, and malignant tumours found in the abdomen, duodenum, thyroid, 
brain, ampullary, pancreas, hepatoblastoma and stomach (Lynch and Fitzgibbons, 1996; 






Figure 3: cDNA of APC gene and extracolonic genotype-phenotype correlations. 
Adapted from Familial Adenomatous Polyposis by Galiatsatos and 
Foulkes, 2006, Am J Gastroenterol, 101(2), p. 385-98. 
 
Despite the classical FAP syndrome associated with APC mutations, there are other 
APC-associated polyposis variants that have been reported. Attenuated FAP (AFAP) is 
characterized by fewer colonic adenomatous polyps (<100) manifested in the colon and 
rectum compared to classic FAP patients, with CRC manifesting at later stage at more 
than 50 years of age (Leppert et al., 1990). Some studies report site-specific mutations 
that caused AFAP (Spirio et al., 1993; Giardiello et al., 1997; Brensinger et al., 1998; 
Soravia et al., 1998): (1) mutations at the 5’end and exon 4 of APC with 2 to more 500 
adenomas with upper GI polyps, (2) exon 9 mutation with 1-150 adenomas with no 
upper GI polyps, and (3) 3’ region mutations with <50 adenomas.   
 
MutYH-Associated Polyposis (MAP) is a polyposis syndrome with autosomal 
recessive inheritance pattern and it was first being reported in three siblings present 
with multiple colonic adenomas and CRC without APC mutation (Al-Tassan et al., 
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2002). It is found to resemble AFAP mostly but some MAP patients also phenotypically 
resemble classic FAP and LS syndromes (Hampel, 2009). Studies report that 
approximately 7-19% of patients showing FAP phenotype but with no APC mutations 
detected are likely to carry biallelic mutations in the MutYH gene (Jones et al., 2009; 
Nielsen et al., 2009; Morak et al., 2010).  
 
There are several conventional methods for detection of APC mutations which included 
the protein truncation test (PTT), DNA sequencing (full gene sequencing of all APC 
exons and intron-exon boundaries), Multiple Ligation-dependent Probe Amplification 
(MLPA) for large deletion and duplication, and differential expression analysis (Powell 
et al., 1993; Roest et al., 1993; Cao et al., 2006b; Rohlin et al., 2011; Hegde et al., 2014). 
Cao et al. reported a 94% APC mutation rate detection with a combination of techniques, 
cDNA-PTT, MLPA and differential expression (Cao et al., 2006b). Due to lower cost 
in sequencing, many diagnostic labs have moved to whole APC gene sequencing 
coupled with MLPA.  
 
Through whole genome sequencing, POLE and POLD1 germline variations have been 
detected in patients with large or more than one colorectal adenomas with previously 
undetectable germline mutation in the known genes that caused CRC (Palles et al., 
2013). POLE p.Leu424Val and POLD1 p.Ser478Asn are the high penetrance variants 
that are found to be associated with the CRC susceptibility by causing a defect in 
mispaired base correction during replication. Hence, tumours carrying these mutations 
always display base substitution mutations. 
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NAP, NTHL1-associated polyposis is the latest addition in the CRC adenomatous 
polyposis subtype. Nth-Like DNA Glycosylase 1 (NTHL1) is a base-excision repair 
gene. A homozygous germline nonsense mutation has been found in three families with 
autosomal recessive inheritance pattern and the carcinomas tested display a non-
hypermutated profile with base transitions for cytosine to thymine (Weren et al., 2015). 
 
Lynch Syndrome (LS) 
Lynch Syndrome (LS) which is the most common hereditary CRC accounts for 2%-4% 
of all CRCs. It is an autosomal dominant inherited CRC caused by germline mutations 
or epimutations in DNA mismatch repair (MMR) genes MLH1 (MutL homolog 1) on 
chromosome 3p21, MSH2 (MutS homolog 2) on chromosome 2p16, MSH6 (MutS 
homolog 6) on chromosome 2p16, and PMS2 (postmeiodic segregation 2) on 
chromosome 7p22 or loss of expression of MSH2 due to deletion in the EPCAM gene. 
The lifetime risk of developing CRC is 50-80% (Stoffel et al., 2009). Before MMR 
genes were identified for their roles in hereditary CRC, the International Collaborative 
Group (ICG) created the Amsterdam criteria to identify LS families for research 
purpose (Vasen et al., 1991).  
 
Amsterdam criteria I (AC1): 
1. One member diagnosed with CRC at young onset (<50 years). 
2. Two affected generations. 
3. Three affected relatives with one of them being the first-degree relative to the 
other two. 
4. No evidence of Familial Adenomatous Polyposis (FAP). 
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Later on, the ICG revised the criteria and developed Amsterdam criteria II in 1999 
(Vasen et al., 1999) so that LS families with germline MMR gene mutations will be 
captured under the more comprehensive criteria. 
 
Amsterdam criteria II (AC2): 
1. At least one member diagnosed <50 years.  
2. Two or more affected generations. 
3. Three or more relatives with LS-associated cancer (CRC, cancer of 
endometrium, small bowel, ureter or renal pelvis) with one of them being the 
first-degree relative to the other two. 
4. No evidence of FAP. 
 
Subsequently, in order to increase the sensitivity in identifying the LS families, a third 
panel, the revised Bethesda guidelines (Umar et al., 2004) has been created. Revised 
Bethesda Guidelines are used for identifying CRC patients whose tumours should be 
tested for microsatellite instability (MSI). 
 
Revised Bethesda Guidelines: 
1. CRC patients diagnosed at age <50 years. 
2. Presence of synchronous or metachronous CRC or other LS-associated tumours 
(colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, 
biliary tract, and brain tumours, sebaceous gland adenomas and 
keratoacanthomas in Muir–Torre syndrome, and carcinoma of the small bowel). 
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3. CRC patients diagnosed at <60 years with tumours characterized as MSI-high 
(presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, 
mucinous/signet-ring differentiation, or medullary growth pattern). 
4. CRC diagnosed in at least one first-degree relative at the age <50 years. 
5. CRC diagnosed in at least two first- or second-degree relatives, regardless of 
age. 
 
Microsatellites are short and tandem repeat sequences of DNA (either mono-, di- or 
trinucleotides) located throughout the human genome (Weber and May, 1989) which 
are prone to accumulation of mutations caused by slippage of polymerases during DNA 
synthesis. If insertions or deletions involving microsatellites occur in the coding region, 
these will generate frameshift mutations that eventually cause protein truncation 
(Jiricny, 2006).  
 
The mismatch repair (MMR) system is responsible for correcting the replication errors. 
MLH1, MSH2, MSH6 and PMS2 interact as heterodimers and once a mismatch is 
detected, a sliding clamp is formed, resulting in re-synthesis and re-ligation by DNA 
polymerase and DNA ligase. Mutations in these MMR genes will lead to accumulation 
of errors in DNA leading to the phenomena termed microsatellite instability (MSI). 
Thus, MSI in tumours has been shown to be a phenotypic indicator of defects in MMR 
genes defect (Vilar and Gruber, 2010).  
 
Since MSI status is one of the criteria under the revised Bethesda guidelines, PCR 
amplification of specific microsatellite repeats or markers has been developed for the 
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detection of MSI in suspected LS patients. The instability is determined by comparing 
the length of the markers in tumour cells to the matched normal cells.  
 
Besides checking on the length of the specific markers, immunohistochemical analysis 
(IHC) of MMR proteins is applied as an alternative to detect MSI complementing the 
genetic testing of LS. Antibodies are used to detect protein expression of the four MMR 
genes and lack of expression of any one of these proteins imply MMR deficiency and 
hence, provide insight into which gene harbours a germline mutation (Cawkwell et al., 
1999). Overall, genetic evaluation for LS can be done by performing MSI testing and/or 
IHC staining on tumours, followed by definitive pathogenic germline mutation in MMR 
or EPCAM genes. 
 
Hamartomatous Polyposis Syndromes (HPS) 
HPS are rare genetic syndromes with hamartomatous polyps that develop in the 
gastrointestinal (GI) tract composed of normal mucosa with distorted architecture 
(Carethers, 2005). These autosomal dominant inherited syndromes include Juvenile 
Polyposis Syndrome (JPS), Peutz-Jeghers Syndrome (PJS) and Phospatase and tensin 
homolog (PTEN) hamartoma tumour syndromes inclusive of Cowden syndrome (CS) 
and Bannayan-Riley-Ruvalcaba syndrome (BRRS).  
 
Key features for JPS are juvenile polyps detected in the GI tract, prominently in the 
colon with CRC risk estimated to reach 39% (Brosens et al., 2007) with germline 
mutation found in either SMAD4 involving the transforming growth factor-beta (TGF-
β) signalling pathway (Howe et al., 1998; Aaltonen and Roth, 2001), or BMPR1A in the 
bone morphogenesis protein (BMP) signalling pathway (Zhou et al., 2001). JPS patients 
 12 
with SMAD4 mutations are commonly displaying gastric polyposis and hereditary 
hemorrhagic telangiectasias. 
 
Phenotypic characteristics of JPS include hamartomatous polyps in the GI tract and 
mucocutaneous melanin pigmentation on the lips and oral mucosa. About 90% of the 
patients carry germline mutation in LKB1 or STK11, a tumour suppressor gene found 
on chromosome 19. Combining point mutation detection and MLPA techniques, the 
mutation detection rate in the PJS patients has improved up to 94% and thus, reduced 
the possibility of a new PJS locus (Aretz et al., 2005).  
 
Other subsets of HPS are CS and the PTEN hamartoma tumour syndrome with 
disorders caused by PTEN mutations. Patients with CS develop clinical phenotypes 
such as macrocephaly (enlarge head), gastrointestinal polyps, mucocutaneous lesions 
and other cancer risks in breast, thyroid and endometrium (Zbuk and Eng, 2007). Risk 
of CRC is considered low in CS patients. However, some recent studies show that there 
is an increased risk of CRC in young patients (Pilarski et al., 2013) and up to 95% of 
CS patients are found to have colonic polyps (Heald et al., 2010).    
 
Hereditary Mixed Polyposis Syndrome (HMPS) 
HMPS, an autosomal dominant hereditary syndrome is characterized by the appearance 
of mixed adenomatous/hyperplastic/atypical juvenile polyps that could become 
malignant. This syndrome was first described in a larger Ashkenazi Jew family, SM96, 
whose affected members displayed a predisposition to mixed polyposis and early onset 
CRC (Whitelaw et al., 1997). Through linkage analysis, the region mapped to 
chromosome 15q13-q14, encompassing CRAC1 and termed HMPS/CRAC1 (Jaeger et 
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al., 2003). Further study from the same research group hypothesized that CRAC1 locus 
harboured low-penetrance variants that caused a higher risk of CRC and two SNPs close 
to GREM1 and SCG5 are strongly associated with CRC risk (Jaeger et al., 2008). 
Subsequently, they reported that HMPS is caused by a 40kb duplication at the 3’ end 
of the SCG5 gene and upstream of the GREM1 locus (Jaeger et al., 2012).  
 
However, our laboratory has found that through genome wide linkage analysis, an 11bp 
deletion found in the bone morphogenesis protein receptor 1A (BMPR1A) gene on 
chromosome 10q23 caused HMPS in one of the Singapore HMPS families (Cao et al., 
2006a). Germline BMPR1A defect in other HMPS families were subsequently reported 
(Cheah et al., 2009). This indicates that BMPR1A should be considered as one of the 
HMPS loci (Cheah et al., 2013).  
 
Familial Colorectal Cancer Type X (FCCTX) 
A fraction of familial CRC patients who fulfil AC1 for LS has no evidence of MMR 
gene defect and are MSI stable when their tumours are assessed by IHC or MSI test. 
These ‘other half of LS’ patients are now given the term FCCTX (Lindor et al., 2005; 
Lindor, 2009). These patients also demonstrated a higher risk of CRC with no 
extracolonic cancers (Llor et al., 2005). It has been suggested that families classified 
under FCCTX may have underlying mutations with high penetrance following the 
Mendelian pattern that are yet to be discovered (Woods et al., 2010). Another study has 
concluded that tumour development in the FCCTX patients is correlated with apoptosis, 
angiogenesis and growth inhibitory pathway with higher migration and invasion ability 
as reflected in the infiltration growth profile as well as necrosis observed in tumours 
(Dominguez-Valentin et al., 2015). 
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1.1.2.2 Sporadic CRC 
Up to 80% of the CRC cases are considered as sporadic CRC, a somatic genetic disease 
with unknown causative genes or pathways but which might be influenced by 
environmental and/or genetic factors. Most patients develop CRC after 60 years with 
common notion that the tumour originates from precursor initiating adenomas over 1 
to 2 decades (Fearnhead et al., 2002).  
 
Sporadic CRC is a complex disease that does not follow only the simple Mendelian 
inheritance pattern. Rather, it is affected by genetic and environmental factors as well 
as gene-environment interactions (Lichtenstein et al., 2000). How these factors 
culminate in the formation of sporadic CRC, however, is still not well understood.    
 
Through studies of population genetics, researchers predict that the disease phenotype 
may either be due to a small number of variants (rare variants) with a large effect size 
but small disease burden due to low allele frequency, or, a large number of variants 
(common variants) each contributing a small effect in the individual (Bost et al., 2001; 
Mackay, 2001). Studies conducted show that common variants might play an important 
role in sporadic CRC and thus, invoking the ‘Common Disease, Common Variant 
(CDCV) hypothesis in CRC (Tenesa and Dunlop, 2009). The CDCV hypothesis 
implied that the major contributors to the susceptibility of a common disease are the 
common or frequent genetic variations in the population with relatively low penetrance 
(Lander and Schork, 1994). When these genetic variations involve nucleotides at the 




1.1.3 Molecular Classification of Colorectal Cancer 
CRC is a heterogeneous disease and is caused by mutations in different pathways, 
resulting in different subtypes with different clinical manifestations that require 
different diagnosis and treatment. Thus, it is critical to have a classification system that 
can distinguish most of the CRC subtypes for accurate prediction prognosis.  
 
Classically, CRC is characterized based on three molecular features, (I) chromosomal 
instability (CIN), (II) MSI and (III) CpG island methylator phenotype (CIMP). CIN, 
the most common feature encounters for 70% of all CRC cases showing anomaly in 
chromosome structures with frequent loss of heterozygosity (LOH) event at tumour 
suppressor loci. CIN tumours display perturbations in major oncogenes such as KRAS, 
NRAS, BRAF and PIK3, loss of chromosome 18q and 17p deletion involving tumour 
suppressors (APC, TP53 and PTEN). Major pathways include Wnt/β-catenin, TGFβ, 
EGFR, MAPK and PI3K (Vogelstein et al., 1988; Fodde et al., 2001). 
 
MSI occurs in 10-15% of CRC and is due to loss of function of DNA mismatch repair 
genes (MLH1, MLH3, MSH2, MSH3, MSH6 and PMS2). CpG island methylation refers 
to DNA methylation occurred at the cytosine base of CpG dinucleotide islands. CpG 
islands situated proximal to the gene promoter regions are unmethylated in the normal 
genome compared to gene promoter hypermethylation observed in cancer genomes. 
Hypermethylation causes gene silencing as well as genomic instability, DNA repair and 




In 2007, CRC was proposed to be classified into five subgroups based on clinical, 
morphological and molecular parameters (Jass, 2007).  
 
Table 2: Classification of CRC into five subgroups   
Subgroups Features 
Group 1 (12%) Origin in serrated polyps, chromosomally stable, MLH1 
methylated, MSI-High, BRAF mutated, CIMP-High 
Group 2 (8%) Origin in serrated polyps, chromosomally stable, partial MLH1 
methylated, MSS and MSI-Low, BRAF mutated, CIMP-High 
Group 3 (20%) Origin in adenomatous or serrated polyps, chromosomally 
instable, *MGMT methylated, MSS/MSI-Low, KRAS 
mutated, CIMP-Low 
Group 4 (57%) Origin in adenomas (sporadic, FAP-associated or MAP), 
chromosomally instable, mostly MSS, CIMP-negative 
Group 5 (3%) Origin in adenomas, chromosomally stable, Lynch syndrome, 
MSI-high, BRAF mutation negative, CIMP-negative 












Figure 4: Molecular classification of CRC based on Domingo et al., 2013. 
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CIN negative, KRAS and/or PIK3CA 









































The Colorectal Cancer Subtyping Consortium was formed so that researchers can 
evaluate the main subtype patterns that are classified based on the gene expression 
subtyping algorithms. The objective of the consortium includes refining the 
classification by integrating all the available molecular data including copy number, 
SNP, mutations, methylation, proteomics as well as microRNA expression so that the 
subtype assignment can be tightly correlated with the disease outcome (Guinney et al., 





Hypermutation and low prevalence of somatic copy number alterations 
(SCNAs), MSI tumours displayed overexpression of DNA damage repair 
proteins, and higher expression of genes with diffuse immune infiltrate 
along with activation of immune evasion pathways. 
CMS2 
Copy number alterations in oncogenes and tumor suppressor genes. 
Tumours showed epithelial differentiation with upregulations of 
downstream targets for WNT and MYC pathways. 
CMS3 
Enriched for several metabolism signatures, in line with metabolic 
adaptation in KRAS-activating mutations and the tumours also displayed 
higher prevalence of CpG island methylator phenotype (CIMP). 
CMS4 
Upregulation of genes involved in the epithelial-to-mesenchymal 
transition (EMT), activation of signatures linked to TGFβ pathway, 
angiogenesis, stromal invasion, matrix remodelling as well as 
inflammatory system. 
Mixed Transition phenotype or intratumoral heterogeneity 
 
Figure 5: Molecular classification of CRC based on The Colorectal Cancer 







With a better classification system, researchers are looking forward to a better 
understanding of cancer biology with a more advanced and effective drug development 
future for the cancer patients. 
 
1.2 Human Genome Variations  
Human genome structure is a very dynamic structure. With the advanced technologies 
in high-throughput sequencing, a spectrum of genomic variation varies from single base 
pair polymorphisms to large alterations involving megabases of nucleotides in large-
scale structural variations (Iafrate et al., 2004). 
 
1.2.1 Single Nucleotide Polymorphism (SNP) 
The basic building block of DNA sequences are nucleotides: Adenine (A), Cytosine 
(C), Thymine (T) and Guanine (G). A SNP is a variation of a single nucleotide that 
happens at certain position across the human genome. SNPs can be found in coding 
regions, non-coding regions or intergenic regions. SNPs occurring in the coding regions 
can be divided into two groups: synonymous (variations that do not perturb the protein 
sequence) and non-synonymous (variations that perturb the protein sequence). The non-
synonymous SNPs can be further divided into missense (a substitution with a different 
amino acid residue) and nonsense (introduction of a premature stop codon that produces 
a truncated protein) variations/mutations.  
 
Generally, most of the SNPs have no effect on the population. However, studies have 
shown that some functional SNPs play important roles in human health including drug 
response and toxicity, as well as disease risks. One of the examples is CYP2A6 alleles 
that have been correlated with metabolism and disposition kinetic of nicotine (Benowitz 
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et al., 2006). Another example is methylenetetrahydrofolate reductase (MTHFR) 
polymorphisms that may predict the efficiency and toxicity of the use of 5-fluorouracil 
(5-FU) as adjuvant chemotherapy in colorectal cancer (Etienne-Grimaldi et al., 2007). 
This has promoted pharmacogenomics studies that aims to satisfy the demand for 
personalized medicine. 
 
With millions of SNPs being found and reported in the public databases (International 
HapMap, 2005), studies of disease association and susceptibility loci are now possible. 
These studies need large sample sizes. Hence, this has encouraged the development of 
high throughput genotyping arrays that will be discussed in Chapter 3 (Syvanen, 2001; 
Jenkins and Gibson, 2002).  
 
1.2.2 Copy Number Variation (CNV) 
Copy number variation (CNV) is a form of structural variation found throughout the 
genome and could be a deletion or duplication in a gene or genomic loci with sizes 
ranging from kilobases (kb) to megabases (Mb) (Iafrate et al., 2004). Through the 
implementation of whole genome scanning approaches in characterizing CNVs, 
methods to study structural variation have changed from cytogenetic analysis using a 
microscope to array CGH, representational oligonucleotide microarray analysis 
(ROMA) and followed by whole genome DNA microarrays (Sebat et al., 2004; Conrad 
et al., 2006; Feuk et al., 2006; Freeman et al., 2006; McCarroll et al., 2006; Redon et 
al., 2006; Carter, 2007; Wong et al., 2007).  
 
Further studies used array-based comparative genomic hybridization (array CGH) 
compared a limited number of healthy individuals to individuals with known 
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chromosomal imbalances (Scherer et al., 2003) and showed that about 50% of these 
CNVs are within gene regions, segmental duplications and gaps in the human genome. 
The authors concluded that CNVs might contribute to underlying disease susceptibility 
and phenotypes (Iafrate et al., 2004).  
 
Subsequently, many studies have been carried out to investigate the role of CNVs in 
human populations in terms of genetic diversity, evolution and disease susceptibility. 
The first generation CNV map has been constructed using 270 HapMap subjects 
through SNP genotyping arrays and array CGH platforms (Redon et al., 2006). The 
authors found that CNV regions encompassed 12% of the total human genome with 
functional genes and elements, disease loci, and segmental duplications with more 
nucleotides involved compared to SNPs, thus indicating the important roles played by 
CNVs (Feuk et al., 2006; Redon et al., 2006).    
 
1.3 Decoding the Human Genome  
With advancing technologies to undertake whole genome sequencing, it has become 
possible to sequence the entire human genome to decode the genes and biological 
information encrypted in the human genome. This will widen our understanding and 
knowledge of the genomic structure and variations, and their functions in human health.  
 
1.3.1 The Human Genome Project, International HapMap Project and 1000 
Genomes Project 
The Human Genome Project that was completed in 2003 has sequenced 3.2 billion base 
pairs of the human genome. Researchers discovered more variations in the human 
genome with SNPs being the most common, with an estimated 10 million SNPs per 
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genome. Subsequently, the International HapMap project created the Haplotype Map 
(HapMap) in order to catalogue common genetic variations in the human genome 
(International HapMap et al., 2007). The project characterized over 3.1 million SNPs 
in 270 individuals from Yoruba (YRI), northern and western European ancestry living 
in Utah from the Centre d’Etude du Polymorphisme Humane (CEPH) collection (CEU), 
Han Chinese from Beijing (CHB) and Japanese from Tokyo (JPT) in three phases 
(Genomes Project et al., 2010).  
 
Next, the 1000 Genomes Project Consortium was formed to build a resource to 
understand further genetic contribution of complex diseases. A total of 1,092 
individuals from 14 populations (Europe, East Asia, sub-Saharan Africa and the 
Americans) have been analysed through whole-genome sequencing, targeted deep 
exome sequencing and SNP genotyping. The consortium validated 38 million SNPs, 
1.4 million short insertions and deletions (indels) and more than 14,000 large deletions. 
It was demonstrated that different populations carry different genetic profiles of 
common and rare variants and the rare variant load differs across functional pathways. 
It was further shown that every individual bears hundreds of rare variants in the non-
coding regions.  
 
Subsequently, the consortium reported the completion of the project with a total of 
2,504 individuals from 26 populations and characterized 88 million SNPs variants, 3.6 
million indels and 60,000 structural variants (The Genomes Project, 2015). The huge 
amount of data generated has facilitated human genetic studies, by providing detailed 
genetic information for variant cataloguing, genechip array designing, genotyping and 
imputation.    
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1.3.2 Cancer Genome Analyses    
In order to investigate the underlying molecular pathogenesis and genetic pathway of 
somatic mutations, whole genome analyses of cancer genomes have been reported. 
Through using the next generation sequencing approach, thousands of mutations have 
been studied i.e. The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Research, 
2008), the Cancer Genome Project (CGP) (Futreal et al., 2004), The Cancer Genome 
Atlas Pan-Cancer analysis project (The Cancer Genome Atlas Research et al., 2013) 
and the International Cancer Genome Consortium (ICGC) (International Cancer 
Genome et al., 2010).  
 
Studies shows that somatic mutations are either ‘driver’ mutations or ‘passenger’ 
mutations (Greenman et al., 2007). Mutations that allow growth selection and thus 
encourage cancer development are called driver mutations while passenger mutations 
do not contribute to cancer development but mostly are by-products that occur during 
cancer cell growth. Through these large-scale sequencing projects, researchers hope 
that human cancer genes can be identified for the application of precision medicine.   
 
Amongst these cancer genome projects, several studies have been carried out using 
limited sporadic CRC samples. A study adopting the exome-wide sequencing approach 
(11 CRC tumours) found that most mutated genes are considered passengers (Wood et 
al., 2007). Another study performed genome-wide copy number analysis on 36 CRC 
tumours with genetic alteration events found in fibroblast growth factor receptor 
(FGFR), epidermal growth factor receptor (EGFR), Erb-B2 receptor tyrosine kinase 2 
and PI3K pathways (Leary et al., 2008). In 2011, whole genome sequencing of nine 
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CRC patients using primary CRC tumours with paired non-cancerous tissues has shown 
fusion events indicating recurrent rearrangements (Bass et al., 2011).  
 
Next, the Cancer Genome Atlas conducted a genome-scale analysis to characterize 
somatic mutations in 276 CRCs including exome sequence analysis, DNA copy number 
alterations, promoter methylation, messenger RNA (mRNA) and microRNA (miRNA) 
expression profiling (Cancer Genome Atlas, 2012). Through this study, they found 
twenty-four mutated genes inclusive of the well characterized APC, TP53, SMAD4, 
PIK3CA and KRAS with frequent mutations also found in ARID1A, SOX9 and 
FAM123B. These could be the potential drivers for CRC. Copy number amplifications 
involving ERBB2 and IGF2 and chromosomal translocations of fusion of NAV2 and 
TCF7L1 have been detected as well. Since ERBB2 and IGF2 regulate cell proliferation, 
these shed light on therapeutic opportunities. Overall, the recurrent genomic alterations 
reported involve five pathways: WNT, TGFβ, PI3K, RTK (receptor tyrosine kinase)-
RAS (rat sarcoma viral oncogene homolog) and TP53.   
 
Cancer genome analyses involve studies of somatic mutations in tumour samples and 
often, these mutations are of high penetrance and located within pathways that are 
known to be involved in CRC development. Low penetrance germline mutations found 
in sporadic CRC, however, are frequently positioned at the non-coding regions, 
contributing subtle effects to CRC risk. With the information generated from cancer 
genome analyses, researchers can now integrate the germline and somatic mutation 




1.3.3 Encyclopedia of DNA Elements (ENCODE) 
ENCODE is a research collaboration funded by the National Human Genome Research 
Institute (NHGRI) in the United States with the main objective of interpreting the 
human sequence generated through the Human Genome Project. The consortium 
examined ~1% of the human genome (29,988kb) during the pilot phase and found that 
most of the nucleotides are pervasively transcribed and are linked to protein coding 
regions. Regions previously thought to contain no transcription activities are now 
identified as having non-protein-coding functions. New transcription start sites and 
regulatory elements featuring chromatin accessibility and histone modification patterns 
have been found, with chromatin structure and the association with replication and 
transcription regulation being studied more in depth (Consortium et al., 2007). 
 
After the initial pilot phase by surveying 1% of the genome, subsequently, the 
ENCODE consortium continues to look at the whole human genome and has thus far 
assigned function to 80% of the whole genome with more than 70,000 promoter regions 
found to be involved in controlling the gene expression process and 400,000 enhancer 
regions involved in regulation of distance gene expression levels (Maher, 2012).   
 
1.3.4 The Singapore Genome Variation Project (SGVP) 
The objective of this study is to study the three major ethnic groups in Singapore as 
well as Southeast Asia, i.e. the Chinese, Malay and Indian (Teo et al., 2009). This 
project created a database consisting of 1.6 million SNPs genotyped from 99 Chinese, 
98 Malays and 95 Indias, using the Affymetrix SNP6.0 Genotyping Chip and the 
Illumina 1M-single DNA Analysis BeadChip. These data can be used as reference 
panels for GWAS projects involving Southeast Asia populations. 
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1.4 Genome-wide Association Study (GWAS)  
Most familial inherited diseases are caused by inherited susceptibility within high-
penetrance mutations but this cannot account for all the familial cases. A proportion 
may also be due to unidentified high-penetrance mutations or unknown mechanisms or 
pathways that presumably involve multiple genes and low-penetrance alleles. The 
detection of low-penetrance susceptibility loci requires large numbers of well-defined 
cases and controls to be genotyped via a genome-wide allelic approach (Houlston and 
Peto, 2004).   
 
The genome-wide allelic approach can be conducted on high density oligonucleotide 
arrays or other platforms that allow a high throughput screening of SNPs. As mentioned 
in the previous section, completion of the Human Genome Project has allowed the 
deposition of millions of SNPs into the public accessible databases and hence, the rapid 
development of SNP genotyping technologies.  
 
With the availability of these high density SNP arrays, researchers can carry out the 
genome-wide allelic studies. Genome-wide allelic studies allow researchers to search 
for the association of common genetic variants or heritable quantitative traits that 
contribute to common diseases in a genome-wide scale and this is termed a genome-
wide association study (GWAS) (Hirschhorn and Daly, 2005). The assumption is, 
through GWAS, researchers will be able to identify causative variants for common 
diseases by comparing the allele frequencies of variants between cases and controls. 
The ultimate goal of GWAS is to be able to predict a high risk group for certain diseases 
and to develop new prevention and treatment strategies. 
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GWAS has since greatly increased our understanding and knowledge of the genetic 
basis of many diseases that have been studied substantially via a GWAS approach. 
Amongst these diseases are type 1 and type 2 diabetes (Scott et al., 2007; Sladek et al., 
2007; Zeggini et al., 2007; Zeggini et al., 2008), colorectal cancer (Tomlinson et al., 
2007a; Zanke et al., 2007; Study et al., 2008; Tenesa et al., 2008b; Tomlinson et al., 
2008; Cui et al., 2011; Dunlop et al., 2012; Jiao et al., 2012; Fernandez-Rozadilla et al., 
2013a; Peters et al., 2013; Zhang et al., 2014a), prostate cancer (Gudmundsson et al., 
2007a; Gudmundsson et al., 2007b; Yeager et al., 2007; Thomas et al., 2008; Al Olama 
et al., 2014; Berndt et al., 2015) and breast cancer (Easton et al., 2007; Hunter et al., 
2007; Long et al., 2012; Chen et al., 2013; Purrington et al., 2014; Rafiq et al., 2014). 
These findings no doubt have been providing valuable insights to the genetic 
architecture of complex diseases.  
 
Since GWAS screens the whole genome for causative variants without assumption 
about the possible location of the casual variants, therefore, it is an unbiased and 
comprehensive approach. However, when millions of probes or markers are being 
tested, experiments must be designed carefully to avoid biases that may contribute to 
false-positive or false-negative associations.  
 
Bias due to population substructure 
In order to achieve higher statistical power, most of the GWAS projects are case-control 
or family-based association studies that recruit up to thousands of study subjects. With 
a large sample size, this has inevitably introduced biases due to unknown population 
stratification (the presence of more than one ethnic group with different allele 
frequencies) and admixture (combination of populations with distinct genetic 
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background) (Hirschhorn and Daly, 2005; Wang et al., 2005; Marchini et al., 2004). 
When population substructure occurs in the study, the allele frequencies among cases 
or controls as well as between cases and controls will be different and hence, the 
association result might be due to the allelic differences introduced by population 
substructure rather than the disease association.  
 
Bias due to technical artifacts   
Technical artifacts are unavoidable when a large amount of markers is involved in 
GWAS with genotyping errors and missing data affecting the result calling that could 
be due to poor DNA quality and the genotype calling algorithm. The consequence 
worsens when batch effect is introduced on top of these artifacts. Batch effects are non-
biological differences that can result from methodological flaws such as cases and 
controls genotyped separately on different plates, by more than one operator on 
different days (Leek et al., 2010). Without corrections, these artifacts will lead to a lack 
of reproducibility of GWAS results.   
 
1.4.1 GWAS and Colorectal Cancer 
To date, more than 20 susceptibility loci associated with CRC have been published 
confirming that part of CRC risk is attributed to common low risk variants. A common 
SNP, rs6983267, located at chromosome 8q24.21 is the first SNP that has been shown 
to be associated with CRC risk and confirmed by several different studies with odds 
ratios (OR) ranging from 1.13 to 1.27 (Tomlinson et al., 2007a; Zanke et al., 2007; 
Tenesa et al., 2008b; Tomlinson et al., 2008; Peters et al., 2013). This SNP falls within 
a gene desert, and several studies have tried to link this SNP to tumour initiation 
(Tomlinson et al., 2007b), somatic CRC tumour evolution (Tuupanen et al., 2008), 
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enhanced Wnt signalling (Tuupanen et al., 2009) and interaction with MYC (Pomerantz 
et al., 2009).  
 
Subsequent GWAS on CRC have identified other susceptibility loci and found 
associations with known pathways based on the proximity to potential candidate genes 
that are known to be involved in CRC risk. Several CRC susceptibility loci have been 
associated with putative regulatory elements targeting BMP2 (Bone morphogenetic 
protein 2), BMP4 (Bone morphogenetic protein 4), SMAD7 (Mothers against 
decapentaplegic homolog 7), CCND2 (G1/S-specific cyclin D2) and GREM1 (Gremlin 
1) that are within the TGFβ/BMP pathways (Broderick et al., 2007; Tomlinson et al., 
2011; Fernandez-Rozadilla et al., 2013b; Kirac et al., 2013; Peters et al., 2012) while 
DUSP10 (Dual specific phosphatase 10), MYC (V-Myc Avian Myelocytomatosis Viral 
Oncogene homolog) and CCND2 are involved in the MAPK (mitogen activated  protein 
kinases) pathway (Houlston et al., 2010; Peters et al., 2012; Whiffin et al., 2014; Al-
Tassan et al., 2015). 
 
Another example involves DNA polymerase, whereby, POLD3 (polymerase (DNA) 
delta 3, accessory subunit) has been identified through GWAS to be involved in CRC 
risk (Dunlop et al., 2012). Recently, POLE (polymerase (DNA) epsilon, catalytic 
subunit) and POLD1 (polymerase (DNA) delta 1, catalytic subunit) have been 
discovered to be mutated with high penetrance in CRC through whole-genome 
sequencing (Palles et al., 2013). Together, these results show that DNA polymerase 
plays a vital role in CRC.  
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Despite the discovery of genes involved in known pathways, findings from GWAS also 
include regions with genes that are not linked to CRC previously. LAMA5 (Laminin 
Subunit Alpha 5) and LAMC1 (Laminin Subunit Gamma 5) are genes from the laminin 
family with functions involved in cell adhesion, cell migration and signalling and hence, 
some authors proposed a vital role for laminin genes in CRC development (Houlston et 
al., 2010; Peters et al., 2012). Another gene, CDKN1A (cyclin-dependent kinase 
inhibitor 1A) encodes p21 that has been shown to affect tumor suppressor pathways 
and thus may have a potential role in CRC (Dunlop et al., 2012). These results show 
that the GWAS approach has the potential to discover new insight into previously 
undiscovered genes or pathways of complex diseases including CRC. 
 
1.4.2 GWAS and ethnicity 
Most of the GWAS projects involved predominantly European-descent individuals, 
raising the question of whether these susceptibility loci can be generalized to other 
populations with potentially disproportionate disease burdens since GWAS involving 
non-European descent individuals are still underrepresented. 
 
Studies have demonstrated geographical structuring among different human 
populations while trying to understand the relationship between ethnicity, ancestry and 
demographic history of world populations (Cavalli-Sforza and Feldman, 2003; 
Bamshad et al., 2004). With available genome-wide data (650,000 common SNPs), a 
study has been carried out on 98 unrelated individuals from 51 different populations 
and the result demonstrated that the distribution patterns of the ancestral allele 
frequencies can distinguish the populations based on geographic regions (Li et al., 
2008).  
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Following this study, another two studies have been carried out to dissect the genetic 
structure of the Han Chinese population to investigate the implication in GWAS, 
bearing in mind that Han Chinese represents one fifth of the entire global population 
while most of the GWAS projects have been conducted on Europeans (Chen et al., 2009; 




Figure 6: Analyses of the first two principal components (A) All Han Chinese; (B) 
Han Chinese from Southern and Northern China. Adapted from 
Genomic Dissection of Population Substructure of Han Chinese and Its 
Implication in Association Studies, by Xu et al., 2009, The American 
Journal of Human Genetics, 85, p.762. 
 
 
Figure 6 shows the analyses of population substructure among Han Chinese (southern 
Han, northern Han, Han Chinese residing in Denver, Chinese Han Beijing from 
HapMap, Beijing, Guangdong and Shanghai provinces) indicating clear clustering 
distinguishing the southern and northern Han Chinese (Xu et al., 2009). When 
Singapore Chinese are included in another study together with other Han Chinese 
individuals, the majority of these individuals clustered under the southern Chinese 
cluster (Chen et al., 2009), in line with the migration history where by the majority of 
A B 
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them are descendant of immigrants from southern China, mainly from Guangdong and 




Figure 7: Population stratification of Han Chinese (A) Han Chinese Beijing from 
HapMap, Shanghai and Singapore Chinese compare to other provincial; 
(B) Three dialect groups from Guangdong compare to other provincial. 
Adapted from Genetic Structure of the Han Chinese Population 
Revealed by Genome-wide SNP Variation, by Chen et al., 2009, The 
American Journal of Human Genetics, 85, p775. 
 
These results indicate that the Han Chinese can be stratified into two main clusters, the 
northern and the southern cluster. Future GWAS involving Han Chinese should account 
for the northern and southern population stratification to minimize the confounding 
effect in the association study. 
 
Recently, several studies have been conducted on East Asian populations (Zhang et al., 
2014b; Zhang et al., 2014a; Jia et al., 2013) while several studies compared the effect 
of the Caucasian identified SNPs in the Asian populations (Xiong et al., 2010; Ho et al., 
2011; Thean et al., 2012; Qiao et al., 2015; Li et al., 2012). GWAS based on East Asian 
populations identified nine new loci as well as a new SMAD7 risk variant that were not 
reported previously in the Caucasian populations while only less than 50% of the 
A B 
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Caucasian identified SNPs were replicated in the Asian population. These results 
suggest that new common variants with CRC predisposition especially in Asian 
populations, remained to be identified. 
 
1.4.3 GWAS and imputation 
Genotype imputation is a common technique in GWAS to statistically infer or predict 
missing genotypes that are not directly genotyped so that researchers can fine-map and 
boost up the association power (Marchini and Howie, 2010). Imputation involves the 
use of a reference panel of haplotypes with denser set of SNPs and impute onto subjects 
that only have a subset of SNPs being genotyped. Hence, markers analysed in GWAS 
can be increased at no additional cost and genotyped data from different platforms can 
be harmonized and combined for meta-analysis. 
 
It is believed that among non-related individuals, the haplotype patterns of each 
individual over short stretches of sequence are identical. Most of the imputation 
methods endeavour to screen for the shared haplotypes between the study subjects and 
the reference panel and impute the missing genotypes in the study subjects. During the 
imputation process, SNPs can be partitioned into two sets: set G for genotyped SNPs 
in both studied samples and reference panel and set N for non-genotyped SNPs in 
studied samples but genotyped in the reference panel. SNPs in set G will then be phased 
into haplotype chunks and the haplotype patterns will be compared between the 
resulting haplotypes and the corresponding haplotypes in the reference panel with the 
assumption that matched haplotypes will have matched SNPs as well (Marchini and 
Howie, 2010; Scheet and Stephens, 2006). 
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Overall, imputation can be used to infer genotypes that did not pass quality control, 
predict genotypes of markers that are not typed in the study and to combine genotypes 
from several studies with different sets of markers based on a reference set. The 
accuracy of the prediction, however, is influenced by the correlation between the non-
genotyped markers and the nearby genotyped markers. Low linkage disequilibrium (LD) 
between the genotyped and non-genotyped will result in low accuracy and vice versa. 
Thus, results generated by imputations should be replicated by checking on the real 
genotypes of the imputed genotypes on a different cases and controls panels (Browning, 










Chapter 2 Aims 
To date, more than 20 susceptibility loci associated with CRC have been published. 
However, most of these GWAS projects involved predominantly European-descent 
individuals with first degree relatives diagnosed with CRC (Tomlinson et al., 2007a; 
Zanke et al., 2007; Tenesa et al., 2008b; Tomlinson et al., 2008; Peters et al., 2013). 
Some studies have shown that there are existing geographical structures among human 
populations, thus susceptibility loci may not be valid in our population (Chen et al., 
2009; Xu et al., 2009).  
 
Hence, the main objective of this project is to perform genome-wide case-control 
association study on stringently defined disease subgroup and healthy controls to 
identify risk loci for sporadic CRC using Affymetrix Genome-Wide Human SNP 6.0 
array. In addition, we aim to verify the Caucasian-identified SNPs with CRC risk in 
Singapore Chinese population besides identifying novel susceptibility loci in this 
population. 
 
Apart from susceptibility SNP loci, CNVs have been shown to potentially contribute to 
underlying disease susceptibility and phenotypes. Thus we also aim to search for CNVs 
(common and rare CNVs) that may contribute to sporadic CRC. 
 
Finally, with the availability of genome-wide genotypes in population specific healthy 
controls, we would like to extend our research work by searching for novel cancer gene 
on the APC mutation-negative familial CRC patients. These aims are summarized in 







(1) Validating CEU-identified  
CRC risk variants
(2) Search for new SNP variant 





To search for novel cancer gene 
on APC mutation-negative 
familial CRC patients
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Chapter 3 Materials and Methods 
Overall, 2,000 CRC cases and healthy controls were arrayed and were described in 
detail in the following section. There were three major approaches that we adopted to 
identify new susceptibility loci and novel gene mutations in the sporadic CRC as well 
as in the familial CRC cases: (1) Affymetrix Genome-Wide Human SNP Array 6.0 for 
genotyping and subsequent SNP and CNV analyses; (2) Taqman SNP genotyping and 
optimized CN assay and (3) Fluidigm SNPtype assay on 192.24 integrated fluidic 
circuits (IFCs) array. In addition, real-time PCR and long-range PCR were performed 
subsequently to verify the findings.  
 
3.1 Patients and Sample collection 
3.1.1 GWAS samples 
Matched mucosa and tumours are routinely harvested from CRC patients undergoing 
resection at SGH. Mucosa specimens collected are usually 10cm away from the tumour 
sites. A total of 1000 sporadic CRC mucosa samples (with the criteria of age 50 and 
above at date of operation and with no dominant family history of FAP and HNPCC) 
archived from year 2000 to 2010 were selected as cases. Patients classified as FAP and 
HNPCC were excluded based on the family pedigree information obtained from 
Singapore Polyposis Registry.  
 
 A total of 1000 age- (matched to three years of the year of operation of the cases) and 
gender-matched blood samples from Singapore Chinese Healthy Study (SCHS) (n=991) 
(Hankin et al., 2001) and the SGH Health Screening Unit (n=69) were selected as 
controls of the study. SCHS recruited Singapore citizens and permanent residents (45-
74 years old) who resided in the government-built housing estates and restricted to two 
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major dialect groups: the Cantonese and the Hokkiens. All the controls were 
interviewed to ensure there was no CRC family history.  
 
Samples were randomized and matched cases and controls were processed together. 
Whole-genome genotyping was performed with Affymetrix GeneChip Human 
Mapping SNP 6 array according to the manufacturer’s protocol as discussed under 
Chapter 3, section 3.2. Arrayed data were checked for the quality and QC assurance 
steps were performed to produce clean and less noisy data with minimum confounding 
as mentioned under Chapter 4, section 4.1. 
 
3.1.2 Familial CRC samples 
Patients who presented with 20 or more adenomas throughout the colon and rectum are 
classified as attenuated FAP. CRC patients diagnosed as polyposis CRC were registered 
with Singapore Polyposis Registry and the proband was interviewed and family 
pedigree with clinical history were documented. Peripheral lymphocyte and tissue 
specimen were collected upon informed consent. The study was approved by the 
SingHealth Centralized Institutional Review Board B. 
 
Protein Truncation test (PTT), multiplex ligation-dependent probe amplification 
(MLPA) and differential expression assay (Cao et al., 2006b) were performed to detect 
APC germline mutations. Amplification of exonic regions and Sanger sequencing were 
performed to screen for germline mutations in MutYH, BMPR1A, PTEN and p53. 
Exclusion of POLD1, POLE and NTHL1 were checked through PCR amplification and 
sequencing at the mutation hot spots. 
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Through technology advancement, fluorescent dye-based genotyping technologies 
have replaced gel electrophoresis-based genotyping methods i.e. polymerase chain 
reaction followed by restriction fragment length polymorphism analysis (PCR-RFLP), 
multiplex PCR and sequencing.  
 
3.2 Affymetrix Genome-Wide Human SNP Array 6.0 (SNP 6 Array) 
The Human GeneChip array utilizes microarray technology to allow screening of 
thousands of SNPs on this high density chip based on allelic discrimination of probe 
(locus- and allele-specific oligonucleotides with 25-mers) and target (digested genomic 
DNA) direct hybridization (Rabbee and Speed, 2006).  
 
The Affymetrix SNP 6 array consists of more than 906,600 SNPs and more than 
946,000 non-polymorphic copy number variation probes. About 482,000 SNPs are 
derived from the earlier generation Mapping 500K and SNP 5.0 Arrays with the 
additional 424,000 SNPs derived from HapMap Project. These SNPs are distributed 
across the human genome including chromosomes X and Y as well as mitochondrial, 
tag SNPs and SNPs in recombination hotspots. 
 
Of the 946,000 non-polymorphic copy number probes, 202,000 targeting 5,677 known 
CNV regions are selected based on the Toronto Database of Genomic Variants (DGV) 
and 744,000 are evenly spaced across the genome. The median inter-marker distance 




Figure 8: Overview of the principle of the Genome-Wide Human SNP 6 Array 
workflow. Adapted and modified from Affymetrix Genome-Wide 
Human SNP 6 Array Data Sheet. 
 
3.2.1 Restriction Enzyme Digestion and Adaptor Ligation 
The workflow for genome-Wide SNP 6 is as shown in Figure 8. Overall, DNA sample 
is digested with StyI and NspI restriction enzymes (RE).  
      
 
The RE (Sty I and Nsp I) digestion reactions were carried out separately under 37°C 
for 120 minutes, followed by 65°C for 20 minutes. The digested DNA is then subjected 
to ligation to adaptor that recognizes the cohesive 4bp overhangs generated from the 
RE digestion.  
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The ligation steps were carried out at 16°C for 180 minutes followed by 70°C for 20 
minutes. The ligated DNA (25µl) was diluted with 75µl of water. The diluted sample 
was ready for PCR.  
 
3.2.2 Polymerase Chain Reaction (PCR) of Ligated Products 
A generic primer which can recognize the adaptor sequence was incorporated during 
PCR to amplify the adaptor-ligated DNA fragments with the fragment size ranging 






The PCR program was as shown below. 
 
 
Three PCR reactions were performed for StyI ligated DNA while four PCR reactions 
using the NspI ligated DNA. PCR products were checked on a 2% agarose gel to verify 
that the amplified products were distributed between 200bp to 1100bp.  
 
3.2.3 PCR Product Purification 
These reactions (3 reactions of StyI PCR products and 4 reactions of NspI PCR product) 
of each sample were then pooled (total ~700µl) before the purification steps. The 
amplified products were subjected to purification step using AMPure XP magnetic 
beads on the Millipore 96 well Multiscreen Deep-well plate coupled with Millipore 
Vacuum Manifold.  
 
First, the pooled PCR products were transferred onto the deep well plate. About 1ml of 
magnetic beads was then added to each of the well containing the pooled PCR products. 
Next, the mixture was mixed by pipetting up and down 5 times and incubated at room 
temperature for 10 minutes. The mixture was then transferred to the 96 well Millipore 
filter plate and the filter plate placed on the vacuum manifold. The vacuum was turned 
on to 20 to 24 in Hg and run for 60 minutes until the mixture had been pulled through 
the filter membrane and the magnetic beads appeared dull indicating the beads were 
dry and then the vacuum was turned off. The filter plate was removed and blotted firmly 
on paper towels until completely dry with no wet spots observed.  
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Subsequently, the filter plate was placed back on the vacuum manifold and vacuumed 
for another 3 minutes. With the vacuum pressure still on at 20 to 24 in Hg, 900µl of 75% 
ethanol (EtOH) was added into each well and allowed to be pulled through the filter for 
about 15 minutes. The vacuum was turned off once the beads were dry and the plate 
was placed at room temperature for another 10 minutes.  
 
These purified products were eluted by dispensing 60µl of cold Elution Buffer into each 
well as close to the beads as possible. This was followed by putting the plate into the 
50°C hybridization oven for 30 minutes to elute the DNA from the magnetic beads. 
After 30 minutes, the plate was removed from the oven and placed on a Jitterburg for 
another 30 minutes so that the beads were resuspended thoroughly with DNA released 
from the beads. Vacuum was applied to the plate until all the liquid containing the 
purified DNA was pulled through the filter membrane and was collected on the elution 
catch plate. 
 
3.2.4 Quantitation, Fragmentation and Labelling 
For quantitation, each of the purified PCR product was diluted 100X before proceeding 
to OD reading. The OD260/OD280 ratio of the purified products must be between 1.8 and 
2.0 and with the yield around 4.5µg/µl. The purified products were checked on 4% 
agarose gel by loading 1.5µl of each of the samples.  
 
After quantitation, 5µl of Fragmentation Buffer was added to 45µl of the purified 
product, followed by adding 5µl of diluted Fragmentation Reagent (0.1U/µl). The 
reactions were placed onto the pre-heated thermal cycler at 37°C for 35 minutes and 
95°C for 15 minutes. The fragmented products (1.5µl) were checked on 4% agarose gel 
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to ensure that the fragmentation step was done successfully with the fragmented 
products below 100bp. 
 
The fragmented products were ready for labelling step by adding the labelling mix as 
shown below and the reactions were placed on the pre-heated thermal cycler block at 
37°C for 4 hours, followed by 95°C for 15 minutes. 
 
 
3.2.5 Target Hybridization 
At this stage, the sample was ready to be loaded onto the Affymetrix SNP 6 array once 
the hybridization was completed. Hybridization master mix was prepared by adding 
four types of hybridization buffer (Hyb Buf) as shown below. 
 
 
The hybridization cocktails were placed on the thermal cycler at 95°C for 10 minutes 
and put on hold at 49°C until ready to be loaded onto the genechip. About 200µl of the 
hybridized product of each sample was injected into the array and loaded into the 
hybridization oven tray and rotated at 60rpm and 50°C for 18 hours. 
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3.2.6 Washing, Staining and Scanning Arrays 
After the hybridization step was completed, the hybridization cocktail was extracted 
from each of the array and 270µl of Array Holding Buffer was injected into the arrays 
and the arrays were allowed to equilibrate to room temperature before the subsequent 
washing and staining steps. 
 
The staining step was a three stage process that required streptavidin phycoerythin 
(SAPE) using Stain 1, antibody amplification step using Stain 2 and a final stain using 
SAPE again. About 600µl of Stain 1, 600µl of Stain 2 and 1ml of Array Holding Buffer 
were placed on holder 1, 2 and 3 on the fluidics station. The washing and staining steps 
were pre-set under the protocol GenomeWideSNP6_450 installed in the fluidics station. 
Once the staining step was over, the array window was checked to avoid air pockets 
and the array was ready for scanning with the Affymetrix 3000-7G scanner. 
 
3.2.7 Data Quality Evaluation with Genotyping Console 3.0 Software 
Genotyping Console (GTC) is a software provided by Affymetrix to analyse the 
Genome-Wide Human SNP6 array data by reviewing the raw data quality as well as 
the genotype data quality to identify outlier samples. Genotyping Console generated 
Intensity QC Table (Table 7) that contained several metrics that must be reviewed for 
each array.  
 
For SNP analysis, one of the most important metric was Contrast QC that reviewed the 
efficiency of the experiment to resolve signals of SNP into three genotype clusters by 
using 10,000 random SNPs on the SNP 6.0 array. Good array data displayed Contrast 
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QC value of more than 0.4. Any sample with Contrast QC < 0.4 indicated experiment 
faulty or bad DNA quality and hence, these samples were re-arrayed.  
 
Besides SNP, the SNP 6 array contains another 946K copy numbers probes for copy 
number analysis. Quality control check for CN probes was based on the Median of the 
Absolute values of all Pairwise Differences (MAPD) between log2 ratios with each pair 
referring to any two markers (SNP or CN probes) that are near or adjacent to each other 
based on the genomic physical position. The MAPD value indicates variability of the 
array. If the variability in the log2 ratio is high, the CN calls will decrease and thus not 
be recommended for further analysis. Hence, any array with MAPD value > 0.5 will be 
excluded. 
 
GTC also generated a genotyping call rate to indicate outliners. Any sample with a call 
rate < 97% was excluded. After removing the outliers, genotyping was performed again 
to obtain optimal call rates. Computed gender was generated and the report was 
compare to the inferred gender to check for inconsistency.  
 
3.3 SNP Genotyping and Optimized CN Assays 
Taqman assay incorporates the use of a primer and probe set together with Taqman ® 
MGB (minor groove binder) probes based on 5’ nuclease chemistry and signal that can 
be measured quantitatively. 
 
3.3.1 Taqman SNP Genotyping 
Taqman SNP Genotyping Assay is based on the 5’ nuclease activity using Taq 
polymerase and the fluorescent reporter signal will be detected during the PCR reaction 
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(Figure 9). Each assay comprises one pair of PCR primers targeting the polymorphic 
sequence and one pair of Taqman minor groove binder (MGB) probes to distinguish 
between the wild-type allele (allele 1) versus the variant allele (allele 2).  
 
A fluorophore reporter dye (VIC or FAM) and a common quencher dye are covalently 
linked to the 5’ and 3’ end of allele 1 and allele 2. The Taqman probes will hybridize 
to the complementary sequence between the forward and reverse primers during 
annealing step. AmpliTaq Gold DNA Polymerase allows elongation when the primers 
are bound to the DNA and the 5’ nuclease activity of the polymerase will cleave the 5’ 
reporter dye of the probes that perfectly match the targeted polymorphic sites. This will 
break the close proximity between the reporter and quencher and hence, relieves the 
quencher effect and permits fluorescence of the fluorophore. Subsequently, detector 
can detect the fluorescence signals indicating the alleles presented in the DNA template. 
 
The Taqman SNP Genotyping reaction is as shown below: 
 
 
Reactions were prepared on 96-well plate and the PCR amplification steps were 
performed using the Applied Biosystems 7500 Fast Real-Time PCR System using the 
standard protocol as below. 
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Genotype data was analysed using the SDS Software v1.4. Samples that were ‘not 
called’ were selected and underwent Sanger Sequencing to confirm the genotype. 
 
    
Figure 9: 5’ nuclease activity of Taqman SNP genotyping assay. Adapted and 




3.3.2 Taqman Copy Number Assay 
As for the Taqman Copy Number Assay, the reaction is based on multiplex PCR 
amplification targeting the CN site with an endogenous gene as reference baseline 
(Figure 10).  
 
The principle is similar to the Taqman SNP genotyping with the exception that at the 
5’ end, the CN target probe is linked to FAM while the reference probe is linked to VIC. 
Similarly, the 5’ nuclease activity of the AmpliTaq Gold DNA Polymerase caused the 
cleavage of the reporter dye but the fluorescence signals is measured between the CN 
amplicon and the reference gene. The downstream analysis is done with CopyCaller 
software provided by the manufacturer. It involves delta-delta Ct (ΔΔCt) based fold 









Figure 10: PCR to amplify targeted CN region and reference DNA in multiplex 
reaction; (A) 5’ nuclease activity of Taqman copy number assay; (B) 
Copy number calculation using CopyCaller software. Adapted and 
modified from Taqman Copy Number Assays Protocol Handbook 
version 2010. 
 
3.3.3 Qiagen Multicopy Reference (MRef) 
A reference baseline is necessary for normalization of the DNA input for copy number 
calculation compared to a reference gene with the assumption that the reference gene 
is always neutral (two copies). The most widely used single copy reference assay is 
either RNase P or TERT. However, when the analysis involves cancer samples, these 
single copy gene reference assays may not be reliable as cancer samples are 
heterogeneous due to the presence of complex chromosomal structure and number.   
 
QIAGEN has developed a multicopy reference (MRef) assay to be incorporated into 
real-time PCR copy number analysis. This reference assay is designed based on three 
criteria: (1) the targeted region should be detectable more than 20 times in a normal 
genome to minimize the copy number perturbation; (2) they should be distributed 
randomly on different chromosomes and (3) short amplicons with the size around 
B 
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100bp or below, and all amplicons should have no more than 10bp difference for all the 
targeted sites.  
 
The primers designed for the MRef reference assay can recognize 41 identical binding 
sites that potentially recognize another 66 near-match priming sites that have a 
mismatch to one the paired primers that will amplify products with the size around 80bp. 
The performance of this reference assay has been tested on 129 normal human genome 
samples of 9 different ethnic populations (Caucasians, Chinese, Indo Pakistan, 
Southeast Asian, Japanese, Mexican-American, African American and Ashkenazi 
Jewish) and the results show that MRef is a better reference normalizer with more 
accurate copy number measurement compared to single copy reference assay (Samuel 
Long, 2013). Copy number calculation is also based on ΔΔCt fold change, using 





Figure 11: Copy number calculation using qBiomarker Data Analysis version 1.2 
 
 51 
We optimized the CN assay by incorporating Taqman CN assays (primers) and Qiagen 
Mref as below: 
 
 
The plate was then placed on the Applied Biosystems 7900HT for PCR amplification. 
 
 
Amplification efficiency and melting curve were checked using SDS Software v2.4, 
followed by CopyCaller Software and qBiomarker Data Analysis version 1.2.   
 
3.4 GWAS Data Analysis  
3.4.1 Golden Helix SNP and Variation Suite (SVS) 
 
Genotypes generated from SNP 6 arrays (CHP files) were imported into the Golden 
Helix SNP and Variation Suite (SVS), software that provides analytical tools for 
GWAS as well as CN analysis. Affymetrix CEL files generated from arrays were 
imported into SVS and quality assurance (QA) procedures were applied to the data to 
identify outliers due to DNA samples with poor quality or questionable identity 
(inconsistency in gender and ethnicity). SNP Genome-Wide analysis and CN analysis 
were analysed differently and thus, different QA procedures and analysis tools were 
applied to reduce noise and batch effect before SNP and CN association test. 
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3.4.1.1 Genome-Wide SNP Analysis 
For SNP Genome-Wide analysis, data from SNP 6 arrays were imported into Golden 
Helix SVS software, followed by the recommended quality control steps to generate 
clean dataset for association test (Figure 12). 
 
Principal Component Analysis (PCA) was applied to correct for population 
stratification as well as batch effect. PCA generated ‘eigenvectors’ and ‘eigenvalues’ 
representing the ‘components’, and these ‘eigenvectors’ with the corresponding 
‘eigenvalues’ were called ‘principal components’. The first few components were 
normally the major contributors to the stratification pattern and thus, were removed to 
subtract out variables that may confound the study. The corrected eigenvalues were 
then re-evaluated and plotted to examine the pattern (Patterson et al., 2006; Price et al., 
2006). 
 
Inflation factor, λ represented the value generated by taking the median value of the 
chi-square distribution from an expected value of a set of markers over the observed 
value of these markers in the study subject, and dividing this median by the 
corresponding chi-square distribution. The distribution was considered ideal when the 
λ value is closed to 1 since chi-square distribution of a confounded association test was 




Figure 12: SNP Workflow using Golden Helix SVS Software 
 
 
After the PCA and inflation factor correction, numeric association test was performed 
on this ‘clean’ numerical dataset with the Correlation/Trend Test. This statistical test 
measured the correlation between two numerical variables (cases and controls) and 
showed any ‘trend’ where either one of these variables may show stronger effect 
compared to other one. 
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After the association test, Manhattan plot was generated to have an overview of the 
association test. SNPs found on significant regions with P value ≤ 1x10-4 were checked 
for the SNP quality by plotting the SNP cluster plot to confirm the SNP genotype 
quality. SNP that was not clustered in three clear genotypes (AA, AB and BB) was 
excluded for the subsequent validation experiment. Only SNP that reach P≤5E-08 was 
considered to achieve genome-wide significance. A conventional P=0.05 assumed 5% 
of the false positive result was due to chance. In GWAS, statistical test was performed 
on millions of SNPs and hence, Bonferroni correction at P <0.05/106 which equals to 
5E-08 is conceptualized (Panagiotou et al., 2012). 
 
3.4.1.2 Genome-Wide Copy Number Analysis 
Figure 13 showed the overall CN workflow under Golden Helix SVS software. For CN 
analysis, raw intensity data from SNP 6 arrays (CEL files) were imported into Golden 
Helix SVS and the software calculated LR (L=log2; R=observed intensity/reference 
intensity). PCA was performed on the LR data to minimize the batch effect and 
population stratification. Subsequently, quality control steps (Derivative Log Ratio 
Spread, wave correction, gender and chromosomal abnormality screening) were 
performed on these LR data.  
 
Derivative Log Ratio Spread (DLRS) measured noisiness in LR data. A high value of 
DLRS demonstrated high poor signal to noise properties in the sample that may lead to 




Genomic waves caused the LR to move up and down like a wave and this phenomenon 
could be contributed by the GC content around each marker or probeset (Diskin et al., 
2008). Hence, SVS computed the GC correlation and corrected the waviness to produce 
new dataset with corrected LR. Any sample with Absolute Wave Factor >0.03 were 
discarded. 
 
Gender screening or verification was performed to check for gender concordance. 
Samples with reported gender inconsistency with the inferred gender were removed to 
avoid sample mix up. Samples were also screened for chromosomal abnormality in 
order to detect large chromosomal aberrations by looking at the average LR across all 
autosomal chromosomes. Samples with extremely high or low average LR value were 
excluded. 
 
After these QC steps, the arrayed samples were re-imported into SVS by excluding all 
samples that failed to fulfil the QC requirement. These ‘cleaned’ dataset were then 
subjected to Copy Number Analysis Method (CNAM). 
 
CNAM Optimal Segmenting was the subsequent step after importing the LR data under 
the CN analysis. Information from the genetic marker map (annotation file containing 
chromosome and physical position for SNPs or CN markers provided by Affymetrix) 
together with the LR data allowed CNAM to discover regions containing markers with 
LR that vary greatly between segments. These segments will most probably contained 




Figure 13: CN Workflow using Golden Helix SVS Software 
 
CNAM provided two segmentation methods, the univariate and multivariate 
segmentation which used the same algorithm but different criteria to determine CNV 
boundaries. Under univariate segmentation, each sample was segmented separately and 
thus, each segment has unique/different cut-point (boundary) among all samples. This 
method was ideal to detect large rare CNV. As for multivariate segmentation, all 
samples were segmented concurrently to look for common CNV regions. These regions 
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tend to harbour smaller CNV, with the assumption that these are conserved regions 
found in cases and the sample size provided sufficient power to detect the association. 
After the CNAM segmenting, CN association test was performed to look for significant 
CNV regions between cases and controls.   
 
3.4.2 Copy Number and Expression Profile Analysis 
Genome-wide expression profiles were available from a subset of tumours previously 
arrayed with Affymetrix U133-Plus 2 array according to manufacturer’s protocol 
(Hong et al., 2010; Low et al., 2016 manuscript in preparation). These arrays were 
‘combated’ to remove batch effect. One way ANOVA analysis between copy number 
status and expression profiles was performed using Partek Genomic Suite (PGS). False 
Discovery Rate (FDR) correction was performed according to Benjamin-Hirschsprung 
algorithm. 
 
3.4.3 Statistical Package for Social Science (SPSS) 
Chi-Square and Fisher’s Exact Test correlating copy number alteration in cases and 
controls of the RP were performed using the Statistical Package for Social Science 
(SPSS) package v21 (SPSS, Chicago, IL, USA). All tests of statistical significance were 
two-sided and differences were taken as significant when P value is <0.05. 
 
3.4.4 Ingenuity Pathway Analysis (IPA) 
IPA is a system that allowed users to transform a list with genes of interest into a set of 
networks based on the information curated under Ingenuity Pathways Knowledge Base 
(IPKB) consisted of genes and their interactions. Probesets from Affymetrix U133 plus 
2 expression array with expression profile perturbed significantly were imported into 
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IPA to investigate the network analysis (www.ingenuity.com/wp-
content/themes/ingenuity-qiagen/pdf/ipa/IPA-netgen-algorithm-whitepaper.pdf).  
 
3.5 Familial CRC Data Analysis  
3.5.1 Microsatellite instability assay 
MSI assay was performed on the matched mucosa and tumour samples using the MSI 
Analysis System from Promega (Madison, WI). About 1 to 2ng of DNA from the 
matched mucosa and tumour samples was used for the multiplex PCR amplification 
according to the manufacturer’s protocol. PCR products labelled with fluorescence dye 
were then separated on ABI PRISM 310 Genetic Analyzer and analysed by ABI 
GeneScan Analysis software. MSS tumour was presented with identical profile as 
matched mucosa in all 5 mononucleotide markers. 
 
3.5.2 Partek Genomic Suite (PGS) 
The CEL files generated from the SNP 6 arrays were imported into Partek Genomic 
Suite (PGS) for bioinformatics analysis and subjected to principal component analysis 
to check for batch effect before the copy number analysis.  
 
Each chip was normalized to make sure total chip intensity of all autosomes was 
consistent and subsequently created a relative measure of chip intensity for SNP and 
CN marker probes separately. Log ratio estimation was calculated based on relative 
chip intensity. Reference intensity was estimated based on median intensity of all 
reference samples for unpaired CN analysis and matched lymphocytic DNA of proband 
for paired CN analysis.  
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Unpaired copy number analysis, loss of heterozygosity (LOH) and allelic-specific copy 
number analyses were performed on CEL files of the affected siblings and 88 ethnicity- 
and gender-matched controls from CRC GWAS that served as the reference baseline in 
order to identify CN deletions shared by both siblings but not in the reference. Paired 
copy number analysis was performed on the two polyps of the proband compared to his 
matched lymphocytic DNA as the reference baseline to investigate whether the second 
allele was deleted. All analyses were performed with PGS. 
 
CN analysis was integrated with loss of heterozygosity (LOH) and allelic-specific copy 
number (AsCN) analysis to detect genomic aberrations that were copy-neutral. This 
approach allowed copy number data being analysed together with SNP data. Only 
deletions called by all three algorithms were followed-up.  
 
LOH applied Hidden Markov Model (HMM) to search for regions that were most likely 
to contain loss events based on the genotype error as well as the expected heterozygous 
frequency at each probe. AsCN estimated number of copies for each allele and was able 
to detect CN imbalance between alleles even when alleles were amplified or deleted 
(http://www.partek.com/white-papers).  
 
3.5.3 Data mining on the confirmed deleted region 
The flanking region surrounding the deleted region was imported into the Repeat 
Masker program (http://www.repeatmasker.org/) to search for repetitive sequences. 
The 1Mb region encompassing the deletion was interrogated with NCBI 
(http://www.ncbi.nlm.nih.gov/), Ensembl (http://www.ensembl.org/) and UCSC 
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(http://genome.ucsc.edu/) databases with emphasis on the chromatin modification 
tracks under ENCODE to identify regulatory elements.  
 
3.6 Imputation 
Imputation is a common practice in GWAS to statistically infer missing genotypes that 
are not directly genotyped by using a reference panel with denser set of SNPs. Figure 
14 showed the workflow of imputation using the Minimac software. 
  
 
Figure 14: Workflow of Performing Imputation using Minimac Software 
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We used East Asian samples (Han Chinese Beijing in China; Han Chinese South in 
China, and Japanese in Tokyo) from 1000 Genomes Project as the reference panel 
(n=278). Genotypes from 1984 samples of GWAS panel that passed the quality control 
of ≥95% call rate and at Hardy Weinberg Equilibrium were included for imputation. 
Strand alignment was checked between arrayed data and the reference set to make sure 
all the SNPs were on the same strand with the reference set, which was on the forward 
strand.  
 
Besides the strand alignment issue, both sets of data must be using the same NCBI build, 
which was Build 37 so that the physical positions were consistent for all the SNPs. 
Allele and coordinate discrepancy were checked between GWAS arrayed panel and the 
reference panel.  
 
In order to ease the computer intensive burden during imputation, genotype data were 
split into chromosomes followed by chunks. This was followed by phasing or haplotype 
estimation of GWAS panel with SHAPEIT software for each chunk (Howie et al., 2012). 
The phased data were used for imputation with Minimac Software.  
 
After imputation was completed, one of the output files was an information (.info) file 
that contained SNP ID, genome physical position, allele frequency and imputed R2 that 
measured the correlation between the predicted allele dosage and the true allele dosage 
of a marker. Higher R2 value indicated the higher accuracy of the genotype imputation. 
This file also contained three statistical values which were looRSQ, empR and empRSQ. 
looRSQ was the estimated R2 for the marker or SNP, while empR represented the 
empirical correlation between the true genotype and the imputed genotype for the 
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marker. Another statistical value, the empRSQ (empR2) measured the actual R2 value 
by comparing the imputed genotype versus the actual genotype.  
Following convention, SNPs with imputed R2>0.3 were included in the association 
study (Li et al., 2010). The imputed R2 and empR2 for genotyped SNPs were checked 
whenever applicable to ensure that imputation of region of interest was reputable.   
 
3.7 Fluidigm SNPtype Assay on 192.24 Integrated Fluidic Circuits (IFCs) 
 Array 
Fluidigm SNPtype Assays are designed based on allele-specific PCR detection 
chemistry, utilizing tagged allelic-specific PCR primers (ASP1/ASP2) and a common 
locus-specific primer (LSP) serving as the reverse primer to produce a tagged target 
amplicon. ASP1 and ASP2 comprise nucleotide tag recognition sequences specific for 
allele 1 and allele 2, respectively.  
 
As shown in Figure 15, a fluorophore reporter molecule (FAM or HEX) at 3’ end 
comprising the tag recognition sequences (for allele 1 and allele 2) and a quencher 
molecule at 5’ end are aligned to form a reporter-quencher pair in close proximity via 
a hairpin structure. This reporter-quencher probe will anneal to the tagged sequence 
during PCR extension step. The reporter molecule is then separated from the quencher 
molecule, resulting in the quencher molecule not in close proximity with the reporter. 
Consequently, the unquenched reporter molecules release fluorescent signal and 
detection of the signal will be carried out to extract the genotype information.  
 
Taqman and SNPtype are based on the reporter-quencher chemistry. However, the 
reporter dye in the Taqman assay binds to the allele specific probe (Figure 9) whereas 
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for SNPtype, reporter dye binds to a tag sequence (a universal tag sequence for all 





Figure 15: Workflow of Fluidigm SNPtype assay on 192.24 IFC Array 
 
 
Targeted SNPs were submitted to Fluidigm website for assays design 
(https://d3.fluidigm.com/) and quality check. To start with SNPtype genotyping, firstly, 




This was followed by 10X assay mix: 
 
 





Thirdly, control line fluid was injected into the IFC array. This was followed by 
pipetting 3µl of 10X assay mix into the assay inlet and 3µl of sample mix into the 
sample inlet on the IFC array. Next, the pressure fluid was added before the IFC array 
was placed into the IFC Controller RX. The assay and sample mix were loaded into the 
array.  
 
Subsequently, the array was placed onto the BioMark HD System and PCR was carried 
out using the selected thermal cycling protocol as shown below: 
 
 
Genotype data was viewed and analysed using Fluidigm SNP Genotyping Analysis 
software. 
 
3.8 Real time RT-PCR assay 
cDNA was synthesized from total RNA using ABI High Capacity cDNA Reverse 
Transcription kit. The 2X RT master mix was prepared and 500ng of RNA was added 




The thermal cycler conditions were programmed as below: 
 
  
The synthesized cDNA was used as template in real-time PCR reactions with ABI 
SYBR® Select Master Mix on MicroAmp® optical 384 well reaction plate in ABI 
7900HT. All reactions were performed in quadruplicate with total reaction volume at 
5µl (20 µl/4). 
 
SYBR® Select Master Mix contained SYBR® GreenER™ dye that was used to detect 
PCR products by binding to the double-stranded (ds) DNA formed during PCR 
amplification. During PCR steps, AmpliTaq® DNA polymerase, UP (Ultra Pure) 
amplified the targeted sequence resulting in dsPCR products that were bind by SYBR® 
GreenER™ dye. When more PCR products were amplified, this will result an increase 




     UDG: Heat-labile Uracil-DNA Glycosylase that allowed dissociation curve to be generated up to 
72 hours 
 
Ct, or “threshold cycle” intersects with the real time PCR reaction curve at the spot 
where a real signal is detected above the background fluorescence. Low Ct value 
indicates high amount of the PCR target, while high Ct value means less PCR target. 
Delta Ct measures the difference between endogenous control (β-actin) that serves as 
the reference and gene of interest. Delta-delta Ct compares the expression of gene of 
interest in two different tissues after normalized to endogenous control. Relative 
quantification (RQ) or fold change between mucosa and polyp (2-ΔΔCt) was determined 
for each gene using the comparative Ct method (Hong et al., 2007). The assay was done 
on six replicates for the matched mucosa and polyp samples.   
 
3.9 Long-range Polymerase Chain Reaction  
The long-range PCR reactions were performed with the Expand Long Range, dNTPack 
(Roche). The 25-μl reaction volume contained 1X expand long range buffer with 
12.5mM MgCl2, 500μM PCR nucleotide mix, 0.3μM of each primer, 1% DMSO, 3.5U 
enzyme mix and 250ng template DNA. The internal control was a 6kb BMPR1A 
amplicon at chromosome 10q23. The amplification reaction consisted of denaturing at 
92°C for 2 min, followed by 10 cycles of 92°C for 10s, 63°C for 15s and 68°C for 8 
min, 25 cycles of 92°C for 10s, 63°C for 15s and 68°C for 8 min plus an extra 20s 
elongation per cycle, and final elongation at 68°C for 7 min as previously performed 
(Cheah et al., 2009).  
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Chapter 4 Data Quality Checks for GWAS Dataset 
Raw intensity files generated from SNP 6 array were analysed using Genotyping 
Console 3.0 (GTC 3.0) software provided by Affymetrix. This software converted the 
signal intensity into genotypes (Chapter 3, section 3.2.7) and also generated several QC 
metrics (call rate, gender, heterozygosity and MAPD) for high quality data. These data 
were imported into SVS for further analysis (Chapter 3, Section 3.4). Subsequently, the 
same dataset was analysed using SVS to adjust for population stratification and batch 
effect to minimize confounders prior to whole genome analyses. 
 
4.1 SNP Data 
All 2000 raw intensity files (CEL files) were imported into GTC 3.0 and CHP files 
containing genotype calls were generated by GTC 3.0. However, due to the limitation 
of the software, these 2000 samples were imported by batches with maximum of 400 
samples in each batch and each batch contained 100 overlapping samples from the 
previous batch.  
 
GTC 3.0 used Birdseed v2, a SNP genotyping algorithm to call the genotypes of the 
arrayed samples. This algorithm used a customized Expectation-Maximization (EM) 
algorithm to fit two-dimensional Gaussians to the SNP data and produced genotype 
calls as well as confidence scores for each sample at the SNP level. Since the Birdseed 
calling algorithm is based on a clustering algorithm, more samples will provide more 
genotype calls and hence, the clustering pattern will be more accurate.  
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Based on the CHP summary, the genotype call rate of each sample (400 samples) in 
each batch were plotted and any sample with call rate less than 97% was considered an 














Figure 16: Call rate for 2000 samples in 6 batches with 100 overlap in each batch. 
 
A total of 49 samples were considered outbound and 37 of these samples were selected 
to be re-arrayed (Table 3) based on the value of Contrast QC, Contrast QC Nsp and 
Contrast QC Sty. These Contrast QC values are zero or negative and/or with a call rate 
below 97%. These samples did not pass the QC criteria primarily due to poor DNA 
quality. When the DNA of these 37 samples were re-extracted and re-arrayed, all of 
these samples passed the QC requirement. These QC steps reduced systematic biases 
caused by low DNA quality samples with high error rates in genotype calls before 
association test is performed. Another six outbound samples were marked for further 
Outbound: 9 Outbound: 14 
Outbound: 4 Outbound: 18 
Outbound: 4 Outbound: 4 
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analysis due to gender inconsistency whereby the computed gender and the inferred 
gender were different. Gender discrepancy might be caused by sample identity 
problems due to sample handling issues i.e. sample mix-ups. 
 





After the initial QC criteria, all the 2000 samples were subjected to gender screening in 
GTC 3.0. Figure 17 showed the gender metrics of all 2000 arrayed samples based on 
CN probes on chromosomes X and Y. Six samples were reported to have unknown 
gender while the rest clustered into two clear clusters to indicate male and female. These 
six samples indicated poor quality of arrayed data and thus were marked to be excluded 
as outliers for the subsequent analysis. Samples with swap gender (n=6) were 
highlighted and thus were also excluded as outliers (Figure 17). 
 
 
Figure 17: Gender metrics of 2000 samples 
 
 
Subsequently, these samples (1986 samples) were checked for the heterozygosity rate 
(Figure 18). Low heterozygosity rate indicates little genetic variability. A large 
variation may affect the genotyping call rate as well as accuracy. None of these samples 
were excluded based on the heterozygosity rate check as the heterozygosity rate of all 








Figure 18: Heterozygosity rate of 2000 samples 
 
 
All the 2000 samples were imported into SVS for subsequent QC steps. Before the 
statistical test was performed, population stratification was checked by including SGVP 
and HapMap samples. PCA of these samples was plotted and shown in Figure 19 (A).  
 
Population stratification occurs when the subjects in the GWAS comprise of individuals 
with different genetic ancestry and thus resulting in positive association test due to 
differences in population rather than the diseases association (Turner et al., 2011).  
 
A total of 16 samples were excluded based on PCA analysis for population stratification 
and the previous QC steps. Twelve samples (unknown gender and gender swapped) as 
well as two samples clustered with Indian ethnicity instead of Chinese and another two 
(N880 and N882) clustered further away from all populations indicates that these 








Figure 19: PCA plot for (A) 2538 samples, (B) 2522 samples after outlier removal 
 
 
These 1984 samples were re-imported into SVS again to have a ‘clean’ dataset. At the 
SNP level, QC assurance steps were applied to exclude SNP with call rate <99%, minor 




healthy controls. SNPs with P value ≤1E-07 were not in HWE and hence excluded from 
the association test. A total of 524K SNPs passed these QC steps and remained in the 
SNP list for GWAS analysis. 
 
Genotyping call rate is indicative of genotype reproducibility and concordance. A Low 
call rate could result from technical failure that led to missing genotypes in the samples. 
Statistical power in detecting an association for rare SNPs (MAF<1%) was very low 
and under power. Hence, removing these rare SNPs will ease the computational and 
multiple testing correction burdens (Turner et al., 2011). As for HWE assumption, 
deviations from HWE indicated possible genotyping errors, population stratification or 
potential association for a disease trait among the cases in the study (Wittke-Thompson 
et al., 2005). Thus, HWE deviation should be checked on the healthy controls but not 
the cases. 
 
Finally, PCA was performed on these filtered SNPs and samples to remove remaining 
latent variables. PCA is a multivariate statistical tool that can calculate variables or PCs 
from large data with the first component consisting as much variation as possible from 
the dataset, followed by the subsequent components (Anderson et al., 2010). Ten PC 
were computed from the data and PC1 versus PC2 (Figure 20A) were plotted, followed 




          
 
          
 
Figure 20: PCA plot for (A) PC1 and PC2, (B) PC2 and PC3, with blue and red   
dots represented cases and controls respectively. 
 
PCA plots demonstrated that PC1 contained a variable for both cases and controls 
whereby samples were distributed into two groups. However, after the first PC was 
adjusted, samples were clustered evenly indicating minimum confounding that might 
lead to false-positive and false negative in the association study. This first PC may be 
reflecting population stratification, family relatedness or experiment artifacts (Clayton 
et al., 2005).  
 
After the PCA adjustment, genomic control or inflation factor (λGC) was computed to 
evaluate further confounding existence. λGC is defined as the median χ2 (1 degree 
freedom) association statistics across all SNPs divided by the theoretical median under 
the null distribution (Reich and Goldstein, 2001). The computed λGC was 1.1 before 








that there is no stratification while λGC > 1 indicates population stratification or other 
confounding factors. λGC < 1.05 is considered benign and acceptable (Price et al., 2010). 
Figure 21 showed the Quantile-quantile plot for assessing distribution of λGC before and 
after 1PC adjustment. 
 
Quantile-quantile plot (Q-Q plot) is a probability plot used as a visualization tool to 
assess the λGC distribution by plotting the observed χ2 values over the expected χ2 values 
in ascending order. Deviation from the line x=y indicates that the distribution is not 
following null hypothesis and this could be due to incorrect expected distribution or 
samples variability or a true association (Wellcome Trust Case Control, 2007).  
 
The GWAS of 14,000 cases on seven common diseases showed that Q-Q plot for each 
of the disease demonstrated minor deviation from the null distribution, except at the tail 
of the observed distribution that corresponded to disease association (Wellcome Trust 
Case Control, 2007) . Q-Q plot demonstrated that all the cases and controls were 
distributed under null distribution with end of the tail deviated slightly from the line of 
equality (x=y) indicating potential disease association.  
 
These observations indicated that stratification and confounders have been 
comprehensively addressed in the SNP dataset and hence, association test can be 
performed subsequently. Efficiency of a GWAS in identifying a true disease association 
depends greatly upon the quality of the data. Compromised data quality in the discovery 
panel will lead to false positive and false negative association results that may affect 







   
 
 
Figure 21: Quantile-quantile plot of observed Chi-squared values versus expected 
Chi-squared values, (A) λGC = 1.1 before PC adjustment; (B) λGC = 1.03 
after 1PC adjustment. 
 
4.2 CN data 
There are about 947 K copy number non-polymorphic probes on SNP 6 array for copy 
number analysis. GTC 3.0 software by Affymetrix was used to access the CN probes 
data based on Median Absolute Pairwise Difference (MAPD) metric indicating 
variability of the array. If the variability is high, the calls will decrease and thus not 
recommended for further analysis. Hence, any array with MAPD value > 0.5 will be 
excluded. Based on this criterion, there were four samples considered as outliers (Figure 
22). 
 
Figure 22: MAPD of 2000 samples. 
A B 
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All 2000 CEL files were imported into SVS to generate the normalized logR ratios (LR) 
followed by quality assurance procedures to filter out samples that will cause poorly 
defined CN segments. The first step is to check for derived log ratio spread (DLRS) 
which measures consistency or noisiness in LR data reflecting low SNP call rates and 
either under or overabundance of identified CN segments. When DLRS is high, this 
indicates poor-signal-to-noise properties and this will lead to difficult CNV detection.  
 
After this QA step was completed, the resulting spreadsheet contained DLRS values 
for each sample by chromosome, genome-wide DLRS values under “ALL” column and 
median of the by-chromosome DLRS values under “Median” column. Histogram was 
plotted (Figure 23) based on the “Median” DLRS values as these values were consistent 
throughout the autosomes. 
 
                    
Figure 23: Histogram of median DLRS 
 
 
Inter-quartile range (IQR) of the median DLRS distribution was calculated to determine 
the outlier threshold by setting the threshold to 1.5 IQR from the third quartile. Sample 
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with median DLRS more than 0.38 were considered outliers and thus were excluded. 
A total of 69 samples were excluded based on this filtering criterion. 
 
The second step of QC assurance was genomic wave detection in the LR data of each 
sample by removing samples with extreme wave factors. Waviness is hypothesized to 
be caused by GC content of the marker probes as well as GC content around the marker 
probes and thus devastates CN detection algorithms.  
 
 
Figure 24: Histogram of Absolute Wave Factor for all samples. 
 
 
IQR of the Absolute Wave Factor (AWF) distribution was calculated to determine the 
outlier threshold by setting the threshold to 1.5 IQR from the third quartile. Sample 
with AWF value more than 0.03 was considered outlier and thus was excluded. A total 
of 123 samples were excluded based on this filtering criterion (Figure 24). 
The third QC step was gender screening to check the concordance between inferred 
gender and computed gender. Under CN analysis, the gender status was computed 
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based on the average observed intensity of the sex chromosomes. Combinations other 
than the usual XX or XY were outliers. SVS reported 22 samples with disagreement 
between the inferred genders compared to the computed gender and hence these were 
excluded from the study. Besides sample mix up that could contribute to the 
disagreement, low intensity of the array data may interfere with gender calling. 
Compared to gender screening under SNP analysis, the X chromosome heterozygosity 
was analyzed based on genotype calls. This could explain the difference in number of 
samples reported as having inconsistent gender under SNP analysis compared to CN 
analysis.  
 
Subsequently, chromosomal abnormality screening was performed to detect large 
chromosomal aberrations based on the average LR on all autosomes. Two samples were 
identified to be outliers. 
 
Overall, a total of 170 samples were excluded based on the four QC steps. 1830 out of 
the 2000 samples were re-imported into SVS for the subsequent PC analysis. This was 
to make sure that batch effects and other technical artifacts can be detected and thus 
corrected to reduce biases prior to CNV association test. Under CN analysis, SVS 
utilized raw signal intensity data that was inherently noisy (Ionita-Laza et al., 2009) to 
infer copy number and hence, the PCA step was extremely important to minimize the 
systematic differences in the signal intensity distribution due to experimental variability 
such as batch effect by plates, array manufacturing lots, scanning and/or processing 
date, source and quality of DNA.   
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After all 1830 samples were imported into SVS, presence of batch effects and technical 
artifacts were interrogated by PCA followed by checking the association pattern across 
the whole genome. A scree plot was plotted for the first 50 eigenvalues as shown in 
Figure 25.  
 
 
Figure 25: Scree plot of 50 eigenvalues for 1830 ‘clean’ samples.  
Axis Y: Eigenvalues; Axis X: Principle components. 
 
 
In order to determine the appropriate number of PCs or eigenvalues that were correct 
for the maximum number of variability represented by the least number of PCs, an 
inflection point resembling an ‘elbow’ on the scree plot was identified. As shown in 
Figure 25, the ‘elbow’ was detected at PC16. Hence, the LR data was corrected for the 
first 16 PCs and CN association test was performed on these PCA-corrected data. Q-Q 
plot (Figure 26) was plotted for the observed Corr/Trend –log10 P value versus the 
expected Corr/Trend –log10 P value to examine whether the PC correction was 
appropriate.  
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Figure 26: Q-Q plots indicating (A) PCs were under-corrected; (B) PC correction 
was appropriate; (C) PCs were over-corrected. Axis Y: Observed χ2; 






When the distribution of the Corr/Trend P value deviated early from x=y line, the PC 
correction is considered under-corrected (Figure 26A). In contrast, it is over-corrected 
when the P value distribution is below the x=y line before deviation (Figure 26C). A 
16PCs correction demonstrated Corr/Trend P value with proper distribution indicating 
appropriate PC correction (Figure 26B). After the PC correction, the desire data points 
(eigenvalues) should be clustered as a single and cohesive grouping. Hence, scatter 
plots of eigenvalues of PC1 versus PC2 as well as PC16 versus PC17 were plotted 
(Figure 27) to investigate the clustering pattern.  
        
     
 
Figure 27: Scatter plots of eigenvalues at (A) PC1 versus PC2 and (B) PC16 versus 
PC17. Green indicated cases and blue indicated controls. 
 
 
Scatter plot of eigenvalues at PC1 versus PC2 showed that the data points were 
distributed irregularly, compared to that after 16 PC corrections which demonstrated a 
more cohesive distribution with no clustering pattern relating to cases and controls 
status. These observations suggested that 16 PC corrections were adequate and the 





1. A total of 16 samples were considered as outliers based on the filtering criteria 
for SNP data and the total sample for the subsequent GWAS analysis was 
reduced from 2000 samples (1000 cases and 1000 controls) to 1984 samples 
(991 cases and 993 controls) 
2. 524 000 SNPs remained for the subsequent SNP association after filtering for 
SNP call rate (≥ 99%), HWE (1x10-7 based on controls) and MAF (0.01). 
3. About 170 samples were considered as outliers based on QC assurance steps for 
copy number analysis and hence, 1830 samples (912 cases and 918 controls) 
remained for CNV association test. 














Chapter 5 Association of Caucasian-Identified Variants with Colorectal 
Cancer Risk in Singapore Chinese 
 
5.1 Aim of the Study 
To investigate the roles and effects of the Caucasian-identified (CEU) CRC risk 
variants in Singapore Chinese (SCH). 
Results published: Association of Caucasian-Identified Variants with Colorectal 
Cancer Risk in Singapore Chinese (Thean et al., 2012) 
 




At the time of this study, GWAS for CRC have unveiled fourteen index SNPs (iSNPs) 
that influence CRC risk in Caucasian populations (Table 4).  
 
Since these findings were based on the Caucasian population and it was known that 
different populations have different allelic frequencies as well as LD patterns, these loci 
have to be replicated to investigate their roles in CRC in other populations. A study has 
demonstrated the existence of genetic heterogeneity in CRC risk between African 
Americans with European Americans. Nine out of the 22 SNPs (10 iSNPs and 11 
nearby SNPs) had odds ratios in the opposite direction that might be due to the 
differences in LD patterns (Kupfer et al., 2010).  
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Table 4: Foursteen Caucasian-identified iSNPs associated with CRC risk  
 
Chromosome SNP ID Gene Symbol 
1q41 rs6687758 DUSP10 
3q26.2 rs10936599 TERC/MECOM 
8q23.3 rs16892766 UTP23 
8q24.21 rs6983267 POU5F1B 
10p14 rs10795668 GATA3 
11q23.1 rs3802842 POU2AF1 
12q13.13 rs7136702 DIP2B/ATF1 
14q22.2 rs4444235 BMP4 
15q13.3 rs4779584 GREM1 
16q22.1 rs9929218 CDH1 
18q21.1 rs4939827 SMAD7 
19q13.11 rs10411210 RHPN2 
20p12.3 rs961253 FERMT1/BMP2 
20q13.33 rs4925386 LAMA5 
 
Data generated from the Affymetrix SNP 6 array were analyzed with SVS to screen for 
the fourteen iSNPs reported to be associated with CRC risk. If the iSNP was not present 
on the SNP 6 array or the minor allelic frequency was too low or not polymorphic 
(MAF<0.01) in SCH, surrogate SNP (sSNP) was identified in Chinese Han Beijing 
(CHB) from HapMap based on LD pattern. sSNP was interrogated in this study when 
the sSNP was in high LD (r2>0.8) and located within 100kb vicinity of the iSNP, and 
with good SNP clustering plot. sSNPs that were identified through fine mapping in 
CEU were included whenever the iSNPs or sSNPs were not available (Carvajal-
Carmona et al., 2011; Tomlinson et al., 2011). 
 
The multiple testing corrections were applied to all the iSNPs and sSNPs identified in 
the SCH cohort with the assumption that only the available risk alleles were tested 
instead of the whole genome association test. Hence, Bonferroni correction of 0.0031 
was applied according to the calculation of P value 0.05/16 SNPs. SNPs with P value 
<0.0031 or within the range of 0.0031<P<0.1 were considered having significant 
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association or demonstrating a trend of associated significance with CRC disease risk. 
Subgroup analysis was performed to investigate the association between the risk alleles 
and the tumour sites as well. 
 
Kaplan-Meier analysis with log rank test was performed to investigate the association 
between genotype and recurrence-free survival rate with recurrence being defined as 
the period measured from operation to local recurrence and/or distant metastasis 
occurrence. Cox regression statistical test was applied to evaluate the independence of 
the covariates as well as the recurrence risk estimation.    
 
5.3 Results and Discussion 
Table 5 below showed the distribution pattern of clinicopathological features of the 
arrayed samples. There were in total 991 cases and 993 controls after the initial quality 
controls steps. There were more male than female subjects (57% vs 43%) and 36% of 
the cases were in the 61-80 year age range, with the median age being 70 years. For 
CRC patients, more than 60% had colon cancer while Dukes A and B (early stage) and 
Dukes C and D (advanced stage) were distributed almost evenly. The majority of the 
tumours of these patients were moderately differentiated. The clinicopathological 













Of the fourteen iSNPs, three iSNPs were not included in this study because no data was 
available. Two iSNPs on chromosomes 14q22 and 19q13.1 were not found on SNP 6 
array while another iSNP on chromosome 20q13.33 was on the SNP 6 array but 




Figure 28: Poor SNP clustering pattern of rs4925386 0n chromosome 20q13.33 
 
 
All three loci have no sSNPs at high LD with r2≥0.8 within 100kb of the iSNPs (Figure 
29 for rs10411210 on chr19q13.11) and hence, this indicated that these regions may not 
harbour any loci that could tag potential causative variants in association with CRC risk 
in SCH cohort. 
 
Figure 29: LD plot for rs10411210 on chr19q13.11 with no available sSNP within 
100kb vicinity. LD was measured as R2. 
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As a result, eleven SNPs (iSNPs and sSNPs) out of the 14 iSNPs were interrogated in 
this study. Only one sSNP, rs3087967, surrogate SNP of rs3802842 on chr11q23.1 
(Figure 30) was found to be significantly associated with CRC risk in SCH (OR=1.22, 
95% CI 1.07-1.38, p=0.002). 
                                                                











Figure 30: LD plot for iSNP rs3802842 and sSNP rs3087967 
 
This observation might be caused by the higher MAF (44%) and the relative higher 
effect size. The pattern of MAF distribution of observed susceptibility loci on several 
diseases were investigated and found that the distribution skewed towards higher MAF 
at >20% compared to MAF between 5-20% in general human populations (Park et al., 
2011). GWAS studies in Caucasians and Japanese populations reported that the 
association of iSNP at chr11q23.1 incresaed disease risk in rectum (OR=1.20, 95% CI 
1.02-1.42) compared to colon. sSNP rs3087967 however, was observed to be associated 
with higher CRC risk in men (OR=1.34, 95% CI 1.14-1.58; P=5x10-4) compared to 
women (OR=1.07, 95% CI 0.88-1.29; P=0.4954), indicating a gender-specific role. 
 
In addition, this study found that five SNPs, rs6687758 (1q41), rs11986063 (8q23.3), 
rs6983267 (8q24.21), rs2059254 (16q22.1) and rs7226855 (18q21.1) demonstrated 
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trend of association with the P value ranging from 0.0031 to 0.1 in SCH CRC patients. 
The P value did not reach statistical significance (P<0.0031) which could be due to an 
insufficient sample size and hence the low statistical power. The MAF of these SNPs 
were also smaller than in the CEU population (Table 6).   
 
Table 6: iSNPs and sSNPs showed trend of association of CRC risk in SCH 
 
Blue indicate iSNPs; italic font indicate sSNPs 
 
The first identified susceptibility loci for CRC risk in the CEU population, rs6983267 
at 8q24.21, was the most frequently replicated iSNP in Caucasian as well as other 
populations (Tenesa et al., 2008a; Kupfer et al., 2009; Matsuo et al., 2009; Xiong et al., 
2010). This SNP was reported to be significantly associated with CRC risk in Japanese 
and northern Chinese populations in recessive model (Matsuo et al., 2009; Xiong et al., 
2010).  
 
This SNP was also found to show a trend of association based on the dominant model 
(OR=1.38, 95% CI 1.13-1.60, Pdominant=0.042) in SCH. The difference in observation 
between these three populations might be due to the Japanese population being 
genetically closer to northern Han Chinese compared to southern Han Chinese (Chen 
et al., 2009). In a Hong Kong study, however, rs6983267 was not found to be associated 
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with CRC risk. Rather, they reported rs7014346 at the same region to demonstrate 
evidence of association with CRC risk (Ho et al., 2011). 
 
Further, iSNP rs10795668 at 10p14 was reported to be associated with a lower cancer 
risk in the rectum in Caucasian and northern Chinese populations. The result of the 
association test for sSNP rs827401 in this study supported these findings (Table 7).  
 
Table 7: Association of the risk locus rs827491 with tumor site 
 
       † Test for heterogeneity 
  * Significant at p<0.1 
 
Another study also reported that this iSNP was linked to lower recurrence risk after 
receiving chemotherapy (Xing et al., 2011). This result, however, was not replicated in 
this study using the sSNP and Kaplan-Meier analysis which showed that the genotype 
was not associated significantly with the recurrence-free survival pattern in all CRC 
patients or patients with chemotherapy. Cox-proportional analysis showed that patients 
presented with the protective allele (AB/BB) had hazard ratio (HR) of 0.91 (95% CI 
0.69-1.20, P=0.50) compared to the reported HR of 0.55 (95% CI 0.30-1.00, P=0.05). 
 
The remaining four SNPs did not demonstrate any association with CRC risk in SCH 




Table 8: iSNPs and sSNPs with no evidence of association with CRC risk in SCH 
   
Blue indicate iSNPs; italic font indicate sSNPs 
 
iSNP rs961253 at 20p12.3 was reported to be significantly associated with CRC risk in 
northern Chinese. However, this result was not replicated in SCH with sSNP rs5005940 
even though the LD pattern in SCH was similar but not identical to the Chinese Han 
Beijing in HapMap (Figure 31), suggesting that genetic heterogeneity exists between 
Northern and Southern Chinese. 
 
    
Figure 31: LD plots for rs961253 and 100kb vicinity in (A) SCH cohort; (B) CHB 




In a study that recruited Northern Chinese as the study population, only 5 out of 10 
SNPs (rs6983267 on 8q24.21, rs10795668 on 10p14, rs3802842 on 11q23.1, rs4939827 
on 18q21.1 and rs961253 on 20p12.3) were replicated in this group (Xiong et al., 2010). 
Another study showed that only 4 SNPs (rs7014346 on 8q24.21, rs4779584 on 15q13.3, 
A B 
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rs10795668 on 10p14 and rs4939827 on 18q21.1 were significantly replicated in Hong 
Kong Chinese study group (Ho et al., 2011). 
 
Even though the two studies recruited Chinese as the study population, analyses of 
population substructure among Chinese demonstrated clear clustering between 
southern and northern Han Chinese (Xu et al., 2009). When SCH were analysed 
together with other Han Chinese, the local Chinese were clustered under the southern 
Chinese cluster (Chen et al., 2009) as shown in Chapter 1, section 1.4.2. Hong Kong is 
a cosmopolitan city with the majority originating from Guangdong, China with 
minority immigrants from different provinces of northern and southern China.  
 
Since these studies did not provide any information on the LD pattern as well as the 
population substructure of the subjects, the results may not be applicable to local 
Chinese in Singapore. CRC is the most frequent cancer in Singapore Chinese 
combining both male and female among all ethnicities (Lee et al., 2015). Hence, this 
study will provide more detail and essential information on the association and effect 
of the Caucasian-identified risk variants in the Singapore Chinese population.  
 
Disparity was observed for associations of reported susceptibility loci with CRC risk 
among Chinese populations (northern Chinese in China, southern Chinese in SCH and 
Hong Kong Chinese). Hence, comparison between these three groups (Table 9) was 









Of the fourteen SNPs included in this study, only four SNPs (rs6983267 at 8q24.21, 
rs10795668 or rs827401 at 10p14, rs3802842 or rs3087967 at 11q23.1 and rs4939827 
or rs7226855 at 18q21.1) were replicated in 2 out of 3 of the Chinese populations, 
implying that functional variants located in these regions might play a vital role in CRC 
risk across different populations. Nevertheless, only rs4939827 is tagging a functional 
gene, SMAD7 that is linked to the TGFα signalling pathway, which is involved in CRC 
tumorigenesis (Pittman et al., 2009). Regions around iSNPs at 10p14 and 11q23.1 
exhibited no functional enhancer elements, indicating that mechanisms responsible for 
the association are yet to be discovered (Niittymaki et al., 2011).  
 
Since rs6983267 is the most replicated variant across different populations as well as 
in other cancer types, several studies performed fine mapping and in depth analysis of 
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this SNP (Tomlinson et al., 2007a; Yeager et al., 2007; Ghoussaini et al., 2008). These 
studies have indicated that this locus resides within a long range enhancer that regulates 
c-Myc expression. This oncogene is situated >300kb downstream of rs6983267 and 
binds to T cell factor 4 (TCF4) and enhances Wnt signalling (Ahmadiyeh et al., 2010; 
Sotelo et al., 2010; Wright et al., 2010). 
 
Furthermore, the region around rs16892766 at 8q23.3 was shown to harbour the 
functional genes EIF3H and UTP23 and this region might play an important role in 
CRC risk for Chinese since the sSNP rs11986063 was replicated in SCH with the 
highest OR at 1.40. No information was available for the other two Chinese populations 
since the iSNP was not polymorphic and thus, not interrogated in their studies. One 
study demonstrated that another SNP, rs16888589 at 8q23.3 binds the EIF3H promoter 
and acts as a transcriptional repressor (Pittman et al., 2010). Subsequently, eQTL 
expression analysis indicated that another gene, UTP23 was correlated with 
rs16888589 and these results led to the conclusion that both genes could be linked 
functionally (Carvajal-Carmona et al., 2011). 
 
Four GWAS identified SNPs at 14q22, 15q13.3, 20p12.3 and 20q13.33 were fine 
mapped onto the BMP pathway. However, all four loci were not replicated in this study. 
Previously, Singapore Chinese HMPS patients were linked to BMPR1A at 10q23 as the 
causative gene (Cao et al., 2006a) instead of CRAC1/HMPS locus at 15q13.3 in 
Ashkenazi Jewish HMPS patients (Jaeger et al., 2003). The disparity indicated that 




5.4 Conclusions      
1. Only six iSNPs or sSNPs at 1q41(rs6695584), 8q23.3(rs11986063), 8q24.21 
(rs6983267), 11q23.1(rs3087967), 16q22.1(rs2059254) and 18q21.1 
(rs7226855) demonstrated evidence of association with CRC risk in SCH. 
2. rs827401 at 10p14 was associated with higher CRC risk in the rectum but not 
disease prognosis in SCH.  
3. The reported iSNPs near BMP loci, BMP4 at 14q22, GREM1 at 15q13.3, BMP2 
at 20p12.3 and LAMA5 at 20q13.33 were not replicated in SCH. 
4. Not all reported CRC susceptibility loci had the same association with CRC risk 
in Chinese populations due to difference in LD structures and allelic frequencies. 
5. Unidentified potential variants associated with CRC risk are yet to be 
discovered. 
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Chapter 6 Genome-wide SNP Association Study 
 
After the QC assurance steps, the PCA-corrected SNP data (524 000 SNPs) were 
subjected to genome-wide association test using SVS software. A total of 991 sporadic 
CRC cases and 993 healthy controls were included in the association test and additive 
model was performed under Corr/Trend test. 
 
6.1 Aim of the study 
To perform genome-wide case-control association study on stringently defined disease 
subgroup and healthy controls to identify risk loci for sporadic CRC using Affymetrix 
Genome-Wide Human SNP 6.0 array in Singapore Chinese. 
 
6.1.1 Sample size used in the study 
GWAS Panel GWAS + SP2 GWAS + RP1 GWAS + RP1 +RP2 
Cases Controls Cases Controls Cases Controls Cases Controls 
991 993 991 1945 1991 1993 2505 3139 
1984 2936 3984 5644 
 
6.2 Background 
The Genome-wide association study (GWAS) is an approach to identify common and 
low-penetrance disease associated loci with no prior knowledge of the physical location 
as well as the biological function by focusing on association between SNPs and disease 
trait based on large series of cases and controls (Easton and Eeles, 2008).   
 
The study of twins to estimate the heritability of causative genes showed that heritable 
susceptibility accounted for 35% of CRC (Lichtenstein et al., 2000) while highly 
penetrant inherited mutations in APC, MUTYH, MMR genes (MLH1, MSH2, MSH6 
 99 
and PMS2), SMAD4, BMPR1A, STK1, LKB1, POLE, POLD1, NTHL1 and PTEN 
accounted for ~5% of the cases (de la Chapelle, 2004; Aaltonen et al., 2007). The 
remaining variation that contributes to CRC risk might be explained by common and 
low-penetrance disease variants.    
  
6.3 Results and Discussion 
6.3.1 CRC GWAS Panel 
Genome-wide association test was performed with Corr/Trend test and additive model 
was selected as the genetic model. Additive model is the most common genetic model 
selected for GWAS by assuming that each copy of the allele/SNP increases the 
associated disease risk with the same effect. Manhattan plot was plotted based on the 




Figure 32: Manhattan plot of 1984 samples for 22 chromosomes. 
 
Manhattan plot was used to represent the significance of the associated SNP with the 




showed the Corr/Trend –log10 P value. The higher –log10 P value, the stronger and 
more significant is the association with the disease risk.  
 
 Overall, there were about 120 SNPs with –log10 P value ≥4 and the SNP clustering 
patterns of all these SNPs were examined. Figure 33 shows the SNP clustering plots of 
the top three SNPs with the most significant –log10 P value (Figure 33A, B, C) 
compared to a SNP with good clustering pattern. 
 
               
 
                   
Figure 33: SNP clustering plots of the top three SNPs (A,B,C) with the most 
significant P value based on association test compared to (D) a SNP on 
chromosome 12 with good SNP clustering pattern. 
 
Based on the SNP clustering pattern, the top three SNPs were ruled out from the 
subsequent validation analysis. The significance of the SNPs was due to wrong 




Corr/Trend P: 2.29E-07 
 
A-2062559 
Corr/Trend P: 5.53E-07 
 
A-8713302 
Corr/Trend P: 3.73E-06 
  
A-2294745 
Corr/Trend P: 4.20E-05 
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algorithm used in this study was Bayesian Robust Linear Model with Mahalanobis 
distance classifier (BRLMM) developed by Broad Institute for Affymetrix Genechips 
(http://www.biostat.jhsph.edu/~iruczins/teaching/misc/gwas/papers/affymetrix2006.p
df). The algorithm normalized the probe intensities and allele signals was estimated for 
each SNP, followed by estimating the three genotypes (AA, AB and BB) based on the 
cluster centres and variance-covariance matrices.  
 
Besides the top three SNPs that were excluded from the subsequent validation analysis, 
only sixteen SNPs from four chromosomes with –log10 P value ≥4 were selected for 
further validation (Table 10). Other SNPs were not included for validation either due 
to bad SNP clustering or only single SNP was found to be significant with no 
neighbouring SNPs supporting the association. 
 





Amongst these 16 SNPs, the SNP with the most significant p value was rs957008 on 
chromosome 8 with the Corr/Trend –log10 P value at 5.45E-06. Since rs957008 was 
the SNP with the most significant P value and was in the vicinity of novel cancer genes, 
the subsequent validation analysis was focused on chromosome 8. There were a total 
of three SNPs found in this region (rs957008, rs10098291 and rs6557991) and two 
genes, TRIM 35 and PTK2B were linked to these three SNPs.  
 
TRIM 35 or Tripartite Motif-containing 35 is a protein coding gene and has been 
reported to act as a tumour suppressor in human hepatocellular carcinoma (Chen et al., 
2015). PTK2B or Protein-tyrosine kinase 2 beta is involved in activation of the MAP 
Kinase signalling pathway, a known pathway in cancer.  (Lev et al., 1995; Zrihan-Licht 
et al., 2000).  
 
Figure 34 showed the regional view of this region selected for further validation. Two 
SNPs, rs957008 and rs6557991 were genotyped using Taqman SNP genotyping assays 
(protocol as described under Chapter 3, section 3.2.1) on another 1000 cases and 1000 
controls that served as the replication panel. Validation is an important practice for 
GWAS for validating the statistical models as well as the concordance of genotypes 









Table 11 shows the summary results of rs957008 and rs6557991 after the validation 
steps. Results demonstrated that P values for both SNPs became less significant and 
did not reach the genome-wide significance after the replication. Since the replication 
was unsuccessful, initiative was taken to increase the sample size by incorporating 




















Table 11: Validation result of rs957008 and rs6557991 on an independent RP 





 a: raw odds ratio; b: odds ratio after adjusted for age, gender and panel. 
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6.3.2 CRC GWAS and SP2 Panels 
SP2 consists of random samples of adult Singapore Chinese, Malay and Asian-Indian 
with the age range from 14 to 95 years old from four cross-sectional studies: Thyroid 
and Heart Study 1982-1985 (Hughes et al., 1990), the National Health Survey 1992 
(Tan et al., 1999), the National University of Singapore Heart Study 1993-1995 
(Hughes et al., 1997), and the National Health Survey 1998 (Cutter et al., 2001).  
 
There were 2,865 blood-derived DNA samples from the SP2 cohort genotyped through 
Illumina arrays (HumanHap 550, 610 Quad, and 1Mduov3 Beadchips). Genechips from 
Illumina and Affymetrix were designed differently with some overlapping markers. 
Hence, a total of 2,099 SP2 samples that were genotyped with Illumina 1M and 610 
were incorporated into this study with the aim to increase the sample size so as to have 
a higher detection power. There were 991 cases and 3092 controls and the total of 
overlapped markers between these two chips were about 109,973 SNPs.     
 
Half of the SP2 controls were aged <50 years, and hence were neither age- nor gender-
matched to the GWAS cases (Figure 35). The cancer histories of the SP2 controls were 
also not known. The rationale for including these controls was that if the candidate 
regions from the original dataset remained significant with the addition of these 








Figure 35: Comparison of age distribution of GWAS, Replication (RP) and SP2 
panels. 
 
Quality assurance as for the previous dataset (SNPs in controls must be in HWE, 
genotype call rate ≥ 0.99, and MAF ≥ 0.01) were applied to the shared SNPs and 99,061 
SNPs remained in the 4083 samples. Since the numbers of SNPs were quite low, 
samples arrayed with Illumina 610 (1,147 samples) were excluded and shared SNPs 
between CRC GWAS dataset and SP2 Illumina 1M (952 samples) were used for 
subsequent analysis. Total sample size reduced to 2936 but shared SNPs were increased 
to 170,000. 
 
Principal component analysis was performed to check for any discrepancy among the 
samples. PCA plots (Figure 36) showed that samples were clustered tightly after PC1 
adjustment indicating minimum confounding factors. The genomic inflation factor  











































Figure 37: Q-Q plot of the combined dataset of 2,936 samples. 
 
 
Subsequently, association test was performed using SNP Test software and Manhattan 
plot at Figure 38 showed the overall association test result. Only chromosomes 6 and 
12 have two or more SNPs in the same vicinity with –log10 P value ≥ 4.  
 
 
Figure 38: Manhattan plot of the combined dataset of 2,936 samples. 
λGC  = 1.02 
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The SNPs at chromosome 6 turned out to be in the MHC region, known to be frequently 
erroneously associated, and hence ignored. The top SNP at candidate region 12p12.2, 
rs1352902, was the same SNP identified from the previous dataset (as shown in Table 
10). Besides this SNP, another SNP, rs951062 (with log10 P value = 4) was also found 
in the previous dataset but with a slightly lower –log10 P value value (3.74). The second 
top SNP identified from the previous dataset, rs1388687, was not found in this 
combined dataset (filtered out). Taken together, three SNPs about 40 kb apart and at 
high linkage disequilibrium (L.D.) with each other (r2 > 0.8) characterized this region 
and hence merit further investigation (Figure 39). The two genes, AEBP2 and PDE3A, 
about 300kb and 550 kb to the left and right of these SNPs respectively, are novel genes 





Figure 39: Locus Zoom plot of two SNPs on chr12p12.2 from the combined dataset 




Table 12 summarized the association test result of the two SNPs on chr12 between CRC 
GWAS panel and CRC GWAS panel combined with SP2 1M. Even though P value for 
both SNPs still did not reach whole genome significance (5E-08), another two 
independent replication panels, RP1 which consisted of 2,000 cases and healthy 
controls and RP2 which consisted of 1,700 cases and healthy controls were selected for 
the validation analysis using Taqman genotyping assays with the hope that the pooled 
analysis of GWAS and RP panels may reach genome-wide significance. 
 
Table 12: Summary table of association test results for rs951062 and rs1352902 






Table 13 below showed the total number of samples available for the subsequent 
validation analysis. Samples with genotypes considered as missed calls under Taqman 
genotyping were called manually and confirmed with Sanger sequencing method. 
Samples were excluded when genotypes were still unable to be determined based on 








Table 13: Numbers of cases and controls of all three panels that were included for 




For healthy controls, the successful rate of genotyping for rs951062 and rs1352902 
were 91% and 92% respectively. Compared to cases, the success rate for cases for these 
two SNPs were higher (96% for rs951062 and 97% for rs1352902). This indicated that 
DNA of the control samples extracted from buffy coat posed a challenge for genotyping. 
The DNA yield was inconsistent among the buffy coat samples and the lower yield 
samples tend to have low DNA quality with 260/280 <1.7.  
 
This phenomenon could be due to the processing procedure for buffy coat during 
centrifugation and recovery of the buffy coat interface. In addition, the time elapsed 
from blood drawing until refrigeration and from refrigeration to centrifugation had a 
significant impact on the DNA yield while automated DNA extractions was better than 
manual (Caboux et al., 2012). A standardized protocol for preparing and storing the 
buffy coat may help to improve the DNA yield as well as the DNA quality and thus, 
can improve the genotype call. 
 
Significance of the P values for replication panel was calculated and the result was 
tabulated in Table 14. P value for rs951062 after adjusted for age, gender and panel was 
4.89E-05 for GWAS panel. However, this SNP was not replicated for both RP1 and 
RP2. The combined association test resulted in P value at 4.85E-05, maintaining the P 
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value from GWAS panel. The second SNP, rs1352902, became less significant with 
the P value from 1.16E-05 to 2.50E-03. Thus, association of both SNPs to CRC failed 
to be validated.    
  
Both SNPs replicated in this study were having the insignificant whole genome P value 
to begin with. A report showed that 73% of associations with borderline genome-wide 
significance (P>5E-08 and P≤1E-07) were successfully replicated in the subsequent 
validation study based on populations of the same ancestry (P≤5E-08) (Panagiotou et 
al., 2012). However, the best candidate in this study did not fall within this range and 
hence, validating the result remained a challenge. Thus, decision was made to embark 
on imputation to increase further the density of markers/SNPs by incorporating 1000 
Genome data to look for any potential candidates that were not among the shared or 


























Table 14: Validation results for rs951062 and rs1352902 for all three panels. 
 
      a: raw odds ratio; b: odds ratio after adjusted for age, gender and panel. 
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6.3.3 Imputed data of CRC GWAS, SP2 1M and 1000 Genome 
Imputation was performed on four panels (Table 15) and the reference baseline used 
were Asian populations (Chinese Han Beijing, Japanese and Chinese Han South) from 
the 1000 Genome Project Phase 1. The total number of markers increased from 170,000 
common SNPs to 34million SNPs. Imputation predicts or imputes genotypes that are 
not directly genotyped by referring to a reference panel with whole genome sequence 
information based on statistical algorithm. The workflow for imputation was described 
under Chapter 3, section 3.6.  
 
Table 15: Four panels of subjects included for imputation. 
 
 
To be more stringent on using the imputed dataset, two subsets of data were created: (I) 
Imputation based on CRC GWAS SNP 6 data and 1000 Genome, and (II) CRC GWAS 
SNP 6 data + SP2 1M Illumina data and 1000 Genome. The association test was 
performed on these two sets of imputed data and a total of 160 SNPs were found to 
have Corr/Trend P value ≤1E-04.  
 
SNP clustering check was performed on all these SNPs and 100 SNPs showed poor 
clustering pattern and Rsq<0.7 and hence were excluded from the subsequent validation 
analysis. About 60 SNPs that passed all the QC criteria (i.e Rsq ≥0.7 and EmpRsq ≥0.9, 
good SNP clustering pattern) were found to be located on chromosomes 5, 8, 9 and 12. 
SNPs located on chromosomes 8 and 9 were linked to two genes, SPIDR and 
ADAMTSL1.  
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SPIDR (Scaffolding Protein Involved in DNA Repair) together with CEBPD 
(CCAAT/enhancer binding protein delta) and PRKDC (protein kinase, DNA-activated, 
catalytic polypeptide) were reported to form FRA8I, a common fragile site spanning 
530kb at 8q11.21 (Brueckner et al., 2013).  
 
Genomic aberrations have been reported in colorectal cancer with the most frequent 
chromosomal rearrangements at 8p (loss) and 8q (gain) during the early stages of 
tumorigenesis and these regions were known as common fragile sites (cFSs) that were 
targeted for breakage during replication (Smith et al., 2006; Brueckner et al., 2013).     
 
Based on this information, SNPs on chr8 posted a great potential in terms of biological 
function and the relevance to CRC. Hence, six SNPs were selected for further validation 
with the most significant Corr/Trend P value at 4.14E-06 using the CRC-SP2 imputed 
dataset. This was by far the highest association reported from the SNP data.  
 
ADAMTSL1 (ADAMTS Like 1 or Punctin) has been hypothesized to be involved in 
cell-cell or cell-matrix interactions (Hirohata et al., 2002). ADAMTS1 from the same 
family was reported to be up-regulated in metastasis carcinoma and may promote 
mammary tumor growth that could serve as a potential therapeutic target in preventing 
breast cancer to metastasize (Ricciardelli et al., 2011). Four out of the 60 SNPs located 
on this region were selected for validation with the most significant association P value 
at 1.49E-05. Interestingly, 10 out of the 60 SNPs were located on chr12, the same region 
that failed to be replicated previously. Six out of the 10 SNPs were selected for 
validation while another two SNPs from chr5, with the total SNPs for validation 





Table 16: Sixteen SNPs selected for validation based on imputation association 
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Validation analyses of these 18 SNPs were performed on the Fluidigm SNPtype Assay 
on 192.24 Integrated Fluidic Circuits (IFCs) Array (Chapter 3, section 3.7). Even 
though 192.24 IFCs array can accommodate up to 24 SNPs on one array, there was no 
other available candidate SNP from the four selected chromosomes due to high GC 
content (>60%). The mean genotype call rate for these 16 SNPs was 99%. 
 
Although imputation was able to estimate genotypes with high accuracy for markers 
that were not directly genotyped in the GWAS and thus was routinely applied in GWAS 
to increase the power, this approach was unable to detect any loci with genome-wide 
significance in this study. Despite all the effort in searching for potential susceptibility 
loci in sporadic CRC, none of the SNP was replicated even though the sample size was 
increased from 1,984 to 5,604 (GWAS+SP2+RP1+RP2 panels) samples and from 
170,000 to 34 million SNPs.  
 
The last attempt was to perform genome-wide association test based on haplotypes. 
With SNP data generated from the high genomic density array, haplotype blocks can 
be detected and haplotype-based association test can be performed.  
 
6.3.4 CRC GWAS Haplotype Association Test 
There are several advantages for performing a haplotype-based association test 
compared to a single-SNP test: (I) fewer tests are performed on haplotype blocks 
compared to single SNP and thus preserving power for reducing false-positive rates, (II) 
the haplotype-based association test includes cis-interactions among nearby SNPs that 
are in the same block, and (III) considers variation that are inherited in the form of 
genomic blocks (Halldorsson et al., 2004).      
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Nevertheless, haplotype-based association is rarely performed on human genotyping 
data due to several reasons: (I) there is no standard consensus on the haplotype 
construction method that lead to different results based on different block detection  and 
(II) there is no answer as to how many SNPs should be in the haplotype (Indap et al., 
2005). 
 
In SVS, the haplotype defining algorithm is based on the LD method (Gusev et al., 
2014a). The study demonstrated that with the availability of high density SNP array 
and large sample size, half of the human genome was represented in blocks with the 
size of 22kb or larger in African and African-American samples and 44kb or larger for 
European and Asian samples.  
 
The haplotype association test was performed using the SVS software by detecting the 
haplotype blocks, followed by the association test. Several criteria were used to detect 
the haplotype block: (I) SNP ≥95% call rate; (II) Paired SNPs with “strong LD” with 
one-sided upper 95% confidence bound for D’ at >0.98 and lower bound >0.7; (III) a 
maximum of 30 markers in a block; and (IV) Maximum 160kb for a block (Gusev et 
al., 2014a).  
 
Based on these criteria, there were about 303,966 markers and 73,333 haplotype blocks. 
The haplotype association test were performed based on per haplotype of which the 
association test was computed to investigate the association between each haplotype 
versus the case and control dependent trait. Five regions that passed genome-wide 
significance and harbour functional genes were highlighted for further analysis (Table 
17).  
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As before, the SNP markers were checked for SNP clustering pattern. Clustering plots 
showed that there was a SNP with poor clustering pattern in each of the five regions. 
The significance of the association test dropped drastically when the problematic SNP 
was removed from the block, suggesting that these results were false positives.  
 
Validation is very important in GWAS since it has been shown that the effect is always 
overestimated in the initial discovery/GWAS panel, and the association tend to become 
modest or small in the subsequent studies (Ioannidis et al., 2001; Studies et al., 2007). 
This discrepancy could be due to (I) differences between the studied populations that 
may not be captured, and (II) the “Jackpot effect” (Hirschhorn et al., 2002) or “winner’s 
curse” (Kraft, 2008) that occurred when the estimated effect of a locus is exaggerated 
compare to the inflated (less significant) effect in the subsequent follow-up study.  
 
Under an ideal situation, when genotype-phenotype association exists, GWAS detected 
this association and it was replicated and validated by the subsequent analysis. However, 
other possibilities may occur, (I) No association and thus GWAS found nothing, (II) 
Associations exist but GWAS missed them, (III) No association but GWAS found false-
positive associations, (IV) Associations exist and GWAS found them but replication 
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studies failed to replicate the association, and (V) inconsistent genetic effect across the 
study populations (Ioannidis, 2007). 
 
In this GWAS study, none of the SNPs reached genome-wide significance after the 
association test was performed. The main issue could be due to low genetic power, a 
common concern in GWAS.  
 
In order to increase the power of GWAS, some studies adopted a study design that 
compared cases with family history of the disease with population controls and hence, 
introduced a biased estimation of a locus’s effect size. Cases recruited under this study 
were CRC patients with no family history and with only 1,000 cases versus 1,000 
controls (before QC) in the discovery panel, low genetic power could be the reason for 
no significant loci with genome-wide significance detected. 
 
Besides low genetic power, inconsistent or heterogeneity in phenotypes and genotyping, 
and biases such as handling procedure for cases and controls (sampling method, storage, 
timing of testing, machine used etc.) may play a part in the analysis outcome (Cordell 
and Clayton, 2005). Hence, experimental design, conduct and procedures are crucial 
while conducting GWAS.  
 
In this study, cases in the GWAS panel and the replication panel were sourced from the 
same centre (Colorectal Surgery Department, SGH) and were collected based on an 
established standard protocol. Controls, however, were collected with different 
sampling methods from different centres. The DNA of controls used in GWAS panel 
were mainly extracted from buffy coat from SCHS (population control) while control 
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DNA samples for the replication panel were derived from lymphocyte of patients 
seeking health screening in SGH (hospital control).  
 
Since the distribution and association patterns in the GWAS healthy controls were 
incomparable with the controls in the replication panel, this may explain why most of 
the selected potential SNPs associated with CRC failed to be replicated while the most 
promising SNP, rs951062 on chr12 only maintained the significance and did not reach 
genome-wide significance.    
 
Despite hundreds of genome-wide association studies that reported susceptibility loci 
associated with complex diseases, these variants explained only a small fraction of the 
heritability of the diseases under study. The unexplained heritability or missing 
heritability could be due to gene-environment interactions (GxE) or more complicated 
pathways (Thomas, 2010; Manolio et al., 2009). Twin studies have estimated that 
heritability of CRC was about 35% (Lichtenstein et al., 2000) while another Swedish 
study that recruited 9.6 million subjects estimated colon cancer heritability to be around 
13% and rectal cancer at 12% (Czene et al., 2002).  
 
Gene-environment interactions involving lifestyle (i.e. smoking) and genetic variants 
in CRC have been proposed to contribute to missing heritability in CRC (Jiao et al., 
2014b). For instance, GxE interactions may pose a joint effect of genes with 
environmental factors that cannot be explained by the separate marginal effects 
(Thomas, 2010). If this is the case, applying GxE interaction analysis to the GWAS 
may enable discovery of new SNP markers or genes associated with sporadic CRC for 
this study. Nonetheless, no environmental factors i.e. smoking, alcohol consumption, 
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BMI etc were available for the CRC cases for further investigation. Hence, collecting 
these data may contribute invaluable insight for future studies.  
 
Although no new SNP variant with genome-wide significance P value was identified, 
the SNP 6 array dataset contributed to the identification of a new SMAD7 risk variant 
in East Asians population (Zhang et al., 2014b). A new SNP, rs7229639 residing within 
the SMAD7 functional gene was found to be significantly associated with CRC risk at 
P = 2.93x10-11, with odds ratio 1.22 (1.15-1.29). This SNP was located about 2.5kb 
upstream of a CEU-identified risk variant, rs4939827, indicating an important role of 
SMAD7 in the aetiology of CRC.    
 
Further, imputed data of rs5275 from this study was used in validating the role of COX-
2 in colorectal tumorigenesis in Singapore CRC patients. COX-2 or Cyclooxygenase-2, 
is an enzyme involved in synthesis of prostaglandins that was associated with 
pathological responses such as inflammation and swelling as well as tumour 
development (Greenhough et al., 2009). Perturbation of COX-2 expression has been 
demonstrated in malignant tumours including CRC (Sano et al., 1995; Yoshimura et al., 
2000; Denkert et al., 2004).  
 
A pilot study found that the C allele (minor allele) of rs5275 served as the protective 
allele that significantly reduced CRC risk by 87% in female subjects. Imputed data of 
rs5275 validated further the observed trend of association (Table 18). P value reached 
0.012 with OR 0.71 (0.54-0.93) for TC and CC genotypes compared to TT genotype in 
female (manuscript in preparation). 
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Table 18: Protective effect of COX-2 polymorphism (rs5275) on CRC risk in 
female SCH  
 
 
Overall, these susceptibility loci only explained a small fraction of the disease risk and 
it is estimated that the heritability based on these loci was only 0.65% suggesting that 
more common variants remain to be identified (Jiao et al., 2014a). 
 
6.4 Conclusions 
1. No new SNP variant that reached genome-wide significance was detected based 
on the CRC GWAS panel consisted of 991 sporadic CRC cases and 993 age- , 
ethnicity- and gender-matched healthy controls in Singapore Chinese 
population. 
2. Increasing sample size and markers by incorporating SP2 controls and by 
imputation did not yield new SNP variant. 
3. Haplotype-based association test did not yield positive result due to poor SNP 
clustering. 
4. CRC GWAS data contributed to the identification of a new SMAD7 risk variant 
in East Asians.  
5. Imputed data of rs5275 was found to be significantly associated with CRC risk 
in female cases. 
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Chapter 7 Genome-wide Association Study Identified Common and Rare 
Copy Number Variants associated with Sporadic Colorectal Cancer Risk 
 
7.1 Aim of the study 
To search for CNVs (common and rare CNVs) that may contribute to sporadic CRC 
since CNVs have been shown to significantly associate with complex diseases. 
 




Copy number variants (CNVs) represent a significant source of human genetic variation 
and could be a consequence of deletion or duplications in a gene or genomic loci with 
the size ranging from one kilobase (kb) to less than five megabases (Mb) (Iafrate et al., 
2004). CNVs were first associated with complex neurological diseases in autism and 
bipolar disorder (Sebat et al., 2007; 2009). Studies also revealed that CNVs cause gene 
expression perturbation, chromatin organization alteration as well as gene regulation in 
the vicinity (Henrichsen et al., 2009).    
 
There are two categories of CNV, common CNVs or CN polymorphisms and rare 
CNVs. Common CNVs occurred in higher frequency in the general population with an 
overall frequency >1%. On the other hand, rare CNVs, also known as microdeletions 
or microduplications, occurred at frequency <1% with greater contribution to 
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carcinogenesis compared to common CNVs (Shlien and Malkin, 2009). These copy 
number alterations are known to be the heritable source of susceptibility to sporadic 
genomic diseases (McCarroll and Altshuler, 2007). 
 
7.3 Results and Discussion   
7.3.1 CNV burden analysis for multivariate segmenting in cases and controls 
The CN segments were discretized into copy number gain (CNG), copy number loss 
(CNL) and copy number neutral (CNN) status after multivariate segmentation for CNV 
burden analysis. Overall, there was no significant difference in the number of gain and 
loss segments between cases and controls (p=0.60). There was also no significant 
difference in CNL and CNG per chromosome between the two subclasses (Figure 40) 
indicating no significant increase of CNV burden in cases over controls. 
 
   
Figure 40: CNV burden for CN loss and CN gain in cases and controls 
 
Contrary to earlier studies in neurological diseases and familial CRC, there was no 
significant increase in overall CNV burden in cases over controls. This observation was 
perhaps not surprising since under multivariate segmentation algorithm, all samples 
were segmented concurrently to look for common CNV regions. Besides, these patients 
were sporadic cases with age of onset 50 years or more and with no family history of 
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CRC. Hence, excess genomic load or burden was not expected. Moreover, there is 
accumulating evidence that indicate that healthy controls harbour substantial CNVs 
with no apparent association with complex disease risks (Iafrate et al., 2004; Sebat et 
al., 2004; Feuk et al., 2006; Freeman et al., 2006; Zarrei et al., 2015).  
 
7.3.2 CNV association testing after multivariate segmentation  
Genome-wide copy number association testing between cases and controls were 
performed based on mean LR values of the CN segments as well as 3-states covariates 
(CNL, CNN and CNG) after the CN segments were discretized based on the LR values. 
Discretizing the LR values into 3-states covariates forced the LR values to fall into three 
categories to ease the computation burden (recommended by SVS) but was less 
accurate compared to using the continuous numerical LR values for the CN association 
test. Hence, in this study, both tests were performed and the results were compared.  
 
Several chromosomal regions achieved genome-wide significance (p≥5E-08) using 
both methods (Figure 41). Three CNV regions with genes of interest which did not 
overlap completely with CNV reported from Database of Genomic Variant (DGV; 
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Figure 41: Manhattan plot of genome-wide CNV association test with three 
selected genes on two chromosomes 
 
These genes of interest were located at chr3, 12 and 14, with –log10 p-value ranging 
from 8 to 12 and CNV segment sizes 0.4 to 3Mb. CNVs implicated in sporadic genomic 
disorders were around 0.5–3Mb (McCarroll, 2008). CN association test performed by 
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numerical regression using LR after univariate segmentation confirmed the CNV region 
on chr14q11 as a rare CNV (Table 19). Amplicons within these CNV loci were then 
chosen to be replicated with an optimized copy number assay.     
 
7.3.3 Rare CNV association testing after univariate segmentation 
Copy number association test between cases and controls was performed using the LR 
values of the segments. Regions located at chromosome 4, 7, 8 and 14 have achieved 




Figure 42: Manhattan plot of CN association for rare variants overlapped with 




The most significant region that achieved –log10 p-value ~16 was a 400kb region traced 
to chr14q11 (Figure 42). This is a known CNV region reported in DGV that comprised 
the T-cell receptor alpha (TRA) genes. This result was considered a spurious 
association as it is probably due to different proportions of T-cells and B-cells present 
in the DNA samples of cases (mucosa) and controls (blood). This resembled the major 
histocompatibility (MHC) loci at chromosome 6 whereby SNPs located in this region 
were always enriched due to immune response. 
 
Similarly, the 84kb region at chromosome 7 comprised the gene encoding the T-cell 
receptor gamma alternate reading frame protein (TARP) and hence, likely to be another 
false positive due to different tissue sources. The neighbouring 437kb region which was 
about 300kb upstream of the TRA region encompassing CHD8 locus seemed more 
promising as it was also identified in the multivariate segmentation procedure. Rare 
CNV could reside within the common CNV regions. Hence, this CHD8 region was 
selected for replication. 
 
7.3.4 Validation of CNV loci by optimized copy number assay   
An optimized copy number assay based on Taqman primers and Qiagen Mref multi-
gene reference was applied to interrogate the CN status of the candidate loci in an 
independent RP. Cases exhibited significantly more copy number alterations (CNA) 






Table 20: Validating common and rare CNV in replication panel 
 
CNV Common Rare  
Gene CD47 RERG ARHGDIB CHD8 
  C* HC# C* HC# C* HC# C*  HC#  
  (N=261) (N=211) (N=253) (N=211) (N=253) (N=211) (N=948) (N=463) 
CNG (%) 17(6.5) 0 (0) 20 (7.9) 0(0) 10 (4.0) 0(0) 22(2.3) 0(0) 
CNL (%) 2 (1.9) 0(0) 1 (0.8) 0(0) 9 (3.6) 4 (1.9)   13(1.4) 0 (0) 
Total 19 (8.4) 0(0) 21 (8.7) 0(0) 19 (7.5) 4 (1.9) 35 (3.7) 0 
p-value <0.001** <0.001** 0.007** 0.000 ** 
  
 
As expected, frequency of CNA in common CNV was higher (~8%) in cases for all 
three genes interrogated compared to rare CNV locus (3.7%) at chr14q11.2. CD47 or 
Integrin Associated Protein resides within the common CNV region at chr3q13.12 
whereas RERG (RAS Like Estrogen Regulated Growth Inhibitor) and ARHGDIB (Rho 
GDP Dissociation Inhibitor Beta) are the two functional genes at chr12p12.3.  
 
CD47, an immunoglobulin-like domain-containing molecule is found to be frequently 
expressed on tumour cells and possessed a “don’t eat me” signal that prevent 
phagocytosis process activated by macrophages (Grimsley and Ravichandran, 2003; 
Vonderheide, 2015). RERG is a member of the RAS superfamily of GTPases and loss 
of expression of this gene was linked to breast tumorigenesis (Finlin et al., 2001). 
ARHGDIB is a GDP-dissociation inhibitor and depletion of its expression was reported 
to inhibit the invasion and migration abilities in pancreatic carcinoma (Yi et al., 2014).    
 
7.3.5 Interrogating gene expression profiles by CN status of CNV loci 
CHD8 (Chromodomain-helicase-DNA-binding protein 8) is an ATP-dependent 
chromatin remodelling factor of the SNF/SW1 family. The SNF/SWI complex is a 
necessary chromatin remodelling factor in modulating gene transcriptions that are 
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repressed by chromatin. This complex cooperates with tissue-specific transcription 
factors so as to balance the suppression of proliferation activities (Wilson and Roberts, 
2011). Of note, a recent study identified germline mutation in SMARCA4, another 
member of the SNF/SW1 superfamily, in several polyposis families (Esteban-Jurado et 
al., 2015). This suggested that members of chromatin remodelers are important 
regulators of the tumorigenesis process. Several studies have implicated that CHD8 is 
a negative regulator of the β-catenin-Wnt signalling pathway (Nishiyama et al., 2012) 
while other studies indicated that it is a positive cell-cycle regulator (Rodríguez-Paredes 
et al., 2009). 
 
The correlation between CHD8 expression pattern and CN status was investigated. 
Expression of the functional H1 domain of CHD8 in tumours normalized to matched 
mucosa did not correlate with that of the CN status. Study using cell lines indicated that 
CHD8 histone binding domain, H1 binds β-catenin in a trimeric complex and thus 
preventing it from activating downstream target genes, such as, cyclin D1 and c-Myc 
(Nishiyama et al., 2012). In CRC study, however, a positive correlation between the 
expression of CHD8 H1 domain with cyclin D1 and c-Myc was revealed (Figure 43).  
 
   
Figure 43: Expression of CHD8H1 compared to cyclin D1 and c-Myc in the tumour 
matched with mucosa. Y-axis: RQ for CCND1 (Panel A) and c-Myc 
(Panel B); X-axis: RQ for CHD8H1 domain. 
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We investigated further the CN status of the CHD8 loci and the expression of 
downstream genes and pathways. Interrogation was performed on a subset of CRC 
tumours with genome-wide expression data generated from Affymetrix U133 plus 2 
arrays in the laboratory (Hong et al., 2010; Low et al., 2016 manuscript in preparation). 
Interestingly, we found that expression of several genes in the matched tumours of copy 
number loss cases (n=3) was significantly perturbed compared to matched tumours of 
CN neutral and gain cases (Table 21A).  
 
Expression of IDO2, STXBP5L, ZFP42, BTBD16, CLDN18, ELF5 and GPR87 were 
up-regulated while CNKSR3 was down-regulated in CHD8 CNL tumours. Network 
mapping using the IPA software showed that these genes were linked by node genes, 
β-catenin, CDX2, TP53 and TNF-α which played important roles in the Wnt, TP53 and 
inflammatory pathways (Figure 44). 
 
 
Table 21: Genes whose expression were perturbed by CNV loci in CRC 
(A) Genes with altered expression in matched tumours of CHD8 copy 
number loss cases (compared to copy number neutral cases; 
n=147) 
Probeset ID Gene Symbol P value Expression 
1568638_a_at IDO2 9.46E-10 ↑ 2.613 
240236_at STXBP5L 8.18E-09 ↑ 1.785 
243161_x_at ZFP42 1.17E-08 ↑ 1.930 
1552566_at BTBD16 3.80E-08 ↑ 1.930 
219936_s_at GPR87 2.67E-07 ↑ 1.581 
1554777_at ZFP42 6.64E-07 ↑ 1.930 
232578_at CLDN18 2.72E-06 ↑ 3.781 
220624_s_at ELF5 5.51E-06 ↑ 2.713 
227481_at CNKSR3 6.10E-06 ↓ 4.688 
FDR cut-off p-value: 8.232e-006     
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(B) Genes with altered expression in matched tumours of 
RERG/ARHGD1B copy number loss cases (compared to copy 
number neutral and gain cases; n=139) 
Probeset ID Gene Symbol P value Expression 
227241_at MUC15 5.35E-07 ↑ 1.582 
220449_at LINC01260 1.40E-06 ↑ 1.649 
1569788_at ST8SIA1 1.51E-06 ↑ 1.454 
FDR cut-off p-value for RERG: 1.83e-006   
FDR cut-off p-value for ARHGDIB: 9.14e-007   
     
        
 
Inhibition of Indoleamine 2,3 dioxygenase-2 (IDO2) has been associated with 
suppression of tumour growth in CRC (Takamatsu et al., 2015) while Syntaxin Binding 
Protein 5 Like (STXBP5L) was reported to be associated with the risk of liver fibrosis 
(Li et al., 2009). Expression of Zinc-finger protein-42, ZFP42 or human Rex-1 (hRex-
1) displayed pluripotent characteristics of tumorigenic stem cells and hence, this 
putative human stem sell markers served as a potential candidate for the study of 
therapeutic application (Mongan et al., 2006; Lin et al., 2014). Claudin-18 (CLDN18) 
was reported to be associated with poor prognosis in CRC (Matsuda et al., 2010). E74 
Like ETS Transcription Factor 5 (ELF5) has been shown to act as tumour suppressor 
in kidney (Lapinskas et al., 2011) while amplification of CNKSR Family Member 3 




Figure 44: Network mapping of genes with expression patterns that linked to 
CHD8 CNL tumours. 
 
Only three genes, MUC15, LINC01260 and ST8SIA1 were up-regulated in ARHGDIB 
and RERG CNL compared to CNN and CNG tumours respectively (Table 21B). 
ARHGDIB and RERG were located on the same common CNV at chr12p12.3 (Table 
19). MUC15 (Mucin 15, Cell Surface Associated) and ST8SIA1 (ST8 Alpha-N-Acetyl-
Neuraminide Alpha-2,8-Sialyltransferase 1) have been previously shown to be highly 
expressed in CRC (Huang et al., 2009; Mitchell et al., 2014). No transcript was 
significantly perturbed by CNA in the CD47 locus after the FDR correction. 
 
In summary, two common and one rare CNVs were demonstrated to be significantly 
associated with sporadic CRC risk in Singaporeans of Southern Chinese descent based 
on discovery from the GWAS panel and validated with an independent RP using an 
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optimized CN assay with pre-designed Taqman copy number assay and MRef as the 
endogenous copy number normalizer.  
 
The common CNV at chr12p12.3 harboured two candidate genes, RERG and 
ARHGDIB which are members of the RAS superfamily of GTPases that were 
previously implicated in tumorigenesis through deregulation of GTPases (Vigil et al., 
2010). Of note, an earlier study with familial CRC have reported that RERGL, an 
RERG-like locus situated about 3Mb downstream from RERG was a rare CNV 
associated with familial CRC risk suggesting that genes in this family are important 
players in CRC (Yang et al., 2014). Our study, however, did not find RERGL to be 
significantly associated with sporadic CRC risk. Interestingly, CN gain in all four loci 
interrogated did not perturb the expression of any gene significantly compared to the 















1. Two common CNVs at chr3q13.12 and 12p12.3 encompassing CD47 and 
RERG/ARHGDIB and one rare CNV at chr14q11.2 encompassing CD47 were 
found to be significantly associated with sporadic CRC in Singapore Chinese 
and these loci were validated in an independent RP. 
 2. Copy number loss at the rare CNV locus consisting CHD8 has a higher effect 
where perturbation of several genes involved in different pathways (Wnt, TP53 
and inflammatory pathways) were predicted compared to the common CNV at 
chr12p12.3, reaffirming that rare CNV has larger effect sizes than common 
CNVs. 
3. Copy number loss in these CNVs appeared to have greater effect than CN gain, 
suggesting that evolving coping mechanisms to compensate for structural 
variant loss may be more difficult and hence less successful than that for 
structural variant gain.    
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Chapter 8 Chromosome 19q13 Disruption Alters Expression of CYP2A7, MIA 
and MIA-RAB4B lncRNA and Contributes to FAP-like phenotype in APC 
Mutation-negative Familial Colorectal Cancer Patients 
 
8.1 Aim of the Study 
To search for putative causative genes in familial colorectal cancer patients with 
attenuated polyposis with undetectable APC, MutYH, BMPR1A, PTEN, p53, POLD1, 
POLE and NTHL1 germline mutations. 
 




As shown in Table 1 (Chapter 1, Section 1.1.2), several genes were reported to be the 
causative genes for polyposis CRC syndrome. Among these genes were APC, MutYH, 
POLD1, POLE and NTHL1. Our laboratory has reported a 94% APC germline mutation 
detection rate through a combination of techniques (Cao et al., 2006b). This implied 
that a subgroup of familial CRC patients with clinical manifestation and inheritance 
pattern similar to classical FAP patients but found to be APC-mutation negative and 
MSI stable may carry underlying defects in novel genes that are yet to be discovered.  
 
In this study, the APC-mutation negative familial CRC patients interrogated were two 
brothers clinically diagnosed as attenuated FAP with undetectable mutations at 
commonly known causative genes for FAP or AFAP patients (Figure 45). The proband, 
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344, was an attenuated FAP patient who presented with 25 adenomatous polyps at age 
23. The elder brother, 447, presented with multiple polyps of adenomatous, juvenile 
and hyperplastic as well as cecal mucinous adenorcarcinoma at age 35. No FAP-
associated extracolonic manifestation was recorded. 
 
 
Figure 45: Family pedigree of APC-mutation negative familial CRC patients, 344 
and 447  
 
 
8.3 Results and Discussion 
8.3.1 Identification of APC-mutation negative familial CRC patients 
APC germline mutation in FAP patients were screened by a combination of techniques 
that enabled a high APC mutation detection rate of over 90% in the families registered 
in the Singapore Polyposis Registry (Cao et al., 2006b). Microsatellite instability assay 
performed indicated that the tumour is microsatellite stable. Hence, a germline mutation 
most likely resided in other tumour suppressors.  
 
Subsequently, screening for germline mutation in MutYH, BMPR1A, PTEN and p53 
genes were performed by direct exonic Sanger’s sequencing and no mutation was found 
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for the proband. It is thus likely that the disease-causing gene lies elsewhere although 
the clinical phenotype mimics that of FAP patients. 
 
8.3.2 Prediction of 5 deletions shared by the two affected siblings 
Genome wide scan was performed on the lymphocytic and polyp DNA of the two 
affected siblings, 344 and 447, in this family (Figure 45) and compared to the genotypes 
of the 88 ethnicity- and gender-matched healthy controls from the CRC GWAS dataset. 
CEL files were imported into Partek Genomic Suite (PGS) software to search for 
germline deletions that were shared by these two brothers but were not found in the 88 
healthy controls. The deletions were called only if they were identified by all three 
algorithms applied, LOH, CN and AsCN analysis.  
 
PGS predicted 5 genomic deletions in four different chromosomes (Table 22). These 
deletions were also found in the polyp DNA of the proband, 344, compared to his 
lymphocytic DNA by paired copy number analysis indicating that the same regions 
were deleted in the polyps. According to Knudson’s two hit hypothesis, the first insult 
was the first hit in the inherited DNA, and any second hit will lead to cancer formation 
(Knudson, 1971). The second hit could be caused by mutation at the intragenic region, 
whole gene deletion, chromosomal loss that due to nondisjunction or somatic 














8.3.3 Validation of the genomic deletion at chromosome 3q28 and 19q13 
Of these five predicted deleted regions, deletions found on chromosome 3q28 and 
19q13 demonstrated functional genes related with CRC. The approximately 6kb 
deletion on chr3 was associated with TP63, while CYP2A7 resides within the 32kb 
deleted region on chr19q13.  
 
TP63, one of the homologs of the TP53 family of transcription factors (Yang et al., 
1998), was found to be highly expressed in several malignant tumours and involved in 
tumour progression, invasion and metastasis (Wang et al., 2016). Long range PCR 
targeting the 10kb fragment of TP63 was performed on lymphocytic DNA of 273 (the 
ethnicity- and gender-matched healthy control), 344 and 447 (the affected siblings) and 
polyp DNA of two different polyps of 344. Results of the long range PCR revealed no 
significant difference in terms of quantity of the targeted TP63 fragment after 
normalization to the internal control BMPR1A (Figure 46). This indicated that no loss 
was found at the lymphocytic DNA as well as the polyp DNA as predicted by PGS and 






Figure 46: The 10kb TP63 product from long range PCR with the 6kb BMPR1A 
from 10q23 as the internal control. B, blood; P, polyp 
 
 
Next, the predicted 32kb deleted region on 19q13 was interrogated. This region was 
deleted in 344 and 447 when compared to 88 healthy controls. The same region was 
also found to be deleted in the polyps under the paired CN analysis (Figure 47). 
 
Figure 47: Regional view of paired copy number analysis for 344 and two polyps. 
 
Long range PCR was performed to amplify a 7.7kb fragment encompassing the 
CYP2A7 gene. The primers, F1-R1 (Figure 48A), were used to amplify the targeted 
sequence on 273 (healthy control), 344 and 447 (the affected siblings), 421 and 424 
(APC mutation positive FAP patients) and matched polyps from 344. Internal control 
was a 6kb fragment from BMPR1A.  
 
Quantitative analysis of the amplified PCR products demonstrated that the intensity of 
the 7.7kb from 344 and 447 were only half of that of 273, 421 and 424 after 
normalization to the internal control (Figure 48B). This observation indicated that 
             273B   344B   447B   344P1  344P2  421B 
TP63 
BMPR1A 
No. of copy  
CN Gain CN Loss 
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template DNA with targeted region was halved for 344 and 447, confirming the deletion 
predicted by PGS.  
 
In addition, the fragment intensity was further reduced for the PCR product from two 
polyps of 344, 344P1 and P2, suggesting that “second hit” based on the Knudson’s two 
hits hypothesis occurred in polyps (Figure 48B). This observation corroborated 
prediction by PGS in which paired copy number analysis between 344 and polyps P1 
and P2 indicated that a 28kb deletion shared by these two polyps was the second hit 
(Figure 47).     
Another set of PCR primers (F3-R3) were designed according to the human genome 
sequence to target a 2.5kb region spanning the intergenic region within the deleted 
region. PCR results clearly indicated that this region was present in lymphocytic DNA 
of 273, 421 and 424 but not in 344, 447, 344P1 and P2 as deletion was expected for this 
family (Figure 48C). Probands of another eleven APC mutation-negative families were 
















   
 
Figure 48: (A) Schematic of the 32kb genomic deletion at chromosome 19q13; (B) 
Long range PCR products amplified with primers F1R1; (C) Long 
range PCR products amplified with primers F3R3; (D) The genes 
and  lncRNA located in the upstream of the 32kb deleted region 
with relevant regulatory element and segmental duplication tracks 
extracted from the UCSC browser.  
 
 
8.3.4 In silico analysis of the 1Mb region encompassing the 32kb deleted region 
Interrogating the 3kb regions of 5’ and 3’ of the 32kb deleted region with the Repeat 
Masker program revealed multiple identical repetitive sequences of the MIR and Alu 
families as shown in Figure 49. Mammalian-wide interspersed repeat (MIR) is an 
ancient molecule and family member of transposable elements (TEs) or ‘jumping gene’ 




32kb deleted region 
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provide transcription-factor binding sites (Thornburg et al., 2006), enhancers (Teng et 
al., 2011), and cis natural antisense transcript (Conley et al., 2008).  
 
Alu element is the most abundant repetitive element in the human genome and a major 
source of new exons whereby spliced exons derived from Alu elements were found in 
many genes (Shen et al., 2011). Since the similarity scores of the Alu elements flanking 
the breakpoints were higher than MIR, the genomic deletion is likely to be mediated by 
a homologous recombination event involving the Alu elements, as reported previously 
in a Singapore FAP family (Cao et al., 2001).      
 
 
Figure 49: Repetitive elements and homology mapping of the 32 kb deletion and 
flanking regions. The figure depicts the repetitive elements in the 
region flanking the deletion.  
 
It is interesting to note that the only gene within the deleted region at 19q13 was 
CYP2A7, a member of a nicotine-metabolizing family of enzymes that was not 
considered as a typical tumor suppressor (Godoy et al., 2002). Hence, it was speculated 
that this deleted region may harbour regulatory elements that could enhance or repress 
neighbouring genes as previously reported (Thean et al., 2010). In silico analysis of the 
deleted region with UCSC Browser tracts revealed a chromatin three-dimensional 
architecture highly inundated with many enhancer, insulator and repressor sites (Figure 
48D). Insulators divide the chromosome into topologically associating domain (TAD) 
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marked by the CCCTC-binding factor (CTCF) proteins and facilitated the interactions 
among transcription regulators and thus, linked the architecture of the human genome 
to its function (Heger and Wiehe, 2014; Ong and Corces, 2014). Hence, the deletion 
could remove a TAD and alter the regulation of candidate tumour suppressors or 
oncogenes within the vicinity (Lupianez et al., 2016; Valton and Dekker, 2016). 
 
Subsequently, a 1Mb region encompassing the deleted region was further investigated 
in silico and several candidate genes were identified. TGFβ1, located about 400kb 
downstream of the deleted region (Figure 48A), is a ligand in the TGFβ signalling 
pathway that is known to play an important role in CRC tumorigenesis (Yu et al., 2014). 
MIA (Melanoma Inhibitory Activity), RAB4B (Ras-Related GTP-Binding Protein 4b) 
and EGLN2 (Egl-9 Family Hypoxia-Inducible Factor 2) were three genes located in 
close proximity at about 35kb upstream of the deleted region (Figure 48D).  
 
MIA and EGLN2 were previously implicated in tumorigenesis processes such as 
cellular proliferation and invasion (Aung et al., 2006; Zhang et al., 2009). RAB4B is a 
small GTPase in the RAS signalling pathway, the dysregulation of which led to cancers 
in many organs (Zrihan-Licht et al., 2000). Two related read-through transcripts that 
were predicted to be long non-coding RNA (lncRNA), MIA-RAB4B and RAB4B-
EGLN2, interspersed these three genes. In addition, another lnc-RNA in the vicinity, 
lncRNA_TCONS_|2_00013113, was predicted by the Encode “transcript of uncertain 





8.3.5 Expression of CYP2A7 and TGFβ1 
Several lines of evidence have indicated that disruption of chromatin boundaries by 
deletion, leading to heterochromatin spreading and enhancer or silencer blocking, were 
stage- and tissue specific (Chetverina et al., 2014; Heger and Wiehe, 2014). Hence, the 
expression of these candidate genes were investigated in the polyps compared to that 
of the matched mucosa in the affected sibling, 344. This was then contrasted to that of 
421, an APC mutation-positive FAP patient with no deletion at 19q13. 
 
The expression of CYP2A7 and TGFβ1 were interrogated by real-time RT-PCR assay. 
The expression of CYP2A7 was diminished ten-fold or more in the two polyps of 344 
compared to the matched mucosa (Figure 50A). On the contrary, the expression of 
CYP2A7 in the polyps of 421 were slightly elevated compared to that of the matched 
mucosa. The expression of TGFβ1, however, was similarly down-regulated in the 
polyps of both 344 and 421 (Figure 50B). 
 
 
      
Figure 50: Relative quantitation (RQ) of (A) CYP2A7 and (B) TGFβ1 transcripts 
in the polyps with respect to matched mucosa of patient 344 with 
deletion at 19q13 and patient 421 with no deletion at 19q13. Axis Y, 






8.3.6 Expression of MIA, lncRNAs and EGLN2 
The expression of the candidate genes 5’ to the genomic deletion, MIA, EGLN2, and 
their related read-through lncRNAs, MIA-RAB4B and RAB4B-EGLN2 were 
investigated. It was not possible to interrogate the expression of RAB4B as it was not 
possible to design primers unique to this transcript alone. 
 
Although the expression of MIA and MIA-RAB4B were consistently down- regulated in 
the polyps of 421 compared to the matched mucosa, the expression of these genes were 
one to five fold up-regulated in the polyps of 344 (Figure 51).  
 
 
          
Figure 51: Relative quantitative of (A) MIA and (B) MIA-RAB4B transcripts in   
the polyps with respect to match-mucosa of 344 and 421. Axis Y, 
Relative quantitation (RQ); Axis X, samples 
 
The minimum and maximum relative quantitation (RQ-min and RQ-max) for MIA-
RAB4B was large in the polyps of 421 as the expression of this read-through lncRNA 
is very low and thus cannot be accurately measured. The expression of EGLN2 and the 
second read-through lncRNA, RAB4B-EGLN2, remain in approximately the same level 
in the polyps of both 344 and 421 compared to their respective mucosa. Furthermore, 
the expression of another lncRNA in close proximity, lncRNA_TCONS_|2_00013113 
(Figure 48D) remained at barely detectable level in the polyps of both 344 and 421. 
A B 
 147 
8.3.7 Expression of a subset of miR-24 regulated genes  
In silico analysis with miRBase (Griffiths-Jones, 2006; Griffiths-Jones, 2010) indicated 
that MIA-RAB4B and RAB4B share the same 3’ untranslated region (UTR) including 
the seed recognition sites for miR-24. This suggests that RAB4B expression could be 
affected by the up-regulation of MIA-RAB4B via miRNA titration (Kumar et al., 2014). 
The expression of RAB4B, however, cannot be investigated independently of MIA-
RAB4B and RAB4B-EGLN2 (Figure 48D).  
 
Therefore other miR-24-regulated, putative MIA-RAB4B competing endogenous RNA 
(ceRNA) targets were searched for. Interrogation using miRNA target prediction 
software identified PIM2 (Pim-2 proto-Oncogene, Serine/Threonine Kinase), TAOK1 
(Thousand and One Amino Acid Protein Kinase), and MAPK7 (Mitogen-Activated 
Protein Kinase 7) as other oncogeneic targets of miR-24. These genes were identified 
by all three predictive software, TargetScan (Agarwal et al., 2015), MiRanda (Enright 
et al., 2003) and PicTar (http://pictar.mdc-berlin.de/).  
 
Interestingly, the expression of PIM2 and TAOK1 were increased up to fifteen and two 
and half folds respectively in the polyps of 344 compared to the matched mucosa whilst 
the expression of these genes in the polyps of 421 remained constant (Figure 52A and 
B). There was, however, no difference in the expression of MAPK7 in the polyps of 344 







      
 
                          
Figure 52: Relative quantitation of (A) PIM2, (B) TAOK1, and (C) MAPK7. Axis 
Y, Relative quantitation (RQ); Axis X, samples 
 
To summarize, the 32kb deleted region on chr19q13 disrupted the chromatin 
organization and altered the expression of several genes in two out of twelve (16.7%) 
of the APC mutation-negative familial CRC families screened. In healthy individuals, 
the frequency of copy number loss in this region from the combined Database of 
Genomic Variants (DGV) (http://dgv.tcag.ca/dgv/app/home) entries is 1.68% (n= 7620 
individuals). Thus, this copy number loss is significantly (Fisher’s Exact Test, p=0.017) 
enriched in a subset of familial CRC patients previously screened to be mutation-
negative in disease-causing genes such as APC and MutYH.  
 
Results generated from this study affirmed further the conclusion of recent studies that 




2014). Bioinformatic analysis of the dataset created from a genome-wide scan of two 
affected siblings of family one (Figure 45) revealed 5 common regions of deletion that 
were not found in 88 ethnicity- and gender-matched healthy controls (Table 21). The 
32 kb deletion at chromosome 19q13 was validated by long-range PCR (Figure 48B 
and C). The data reemphasized that bioinformatics analysis has to be corroborated by 
independent secondary assay. 
 
The 32 kb deletion encompassed the CYP2A7 gene only (Figure 48A). It appeared that 
both copies of CYP2A7 gene were lost in the polyps of the proband, 344, by 
bioinformatic analysis as well as long-range PCR experiments (Figure 48B). The loss 
of the wildtype allele (the two hit hypothesis) was consistent with it being a tumour 
suppressor gene. Thus, it was not surprising that CYP2A7 expression in the polyps 
compared to the matched mucosa of 344 was very much down-regulated while the 
expression in the polyps of 421 (the APC mutation-positive patient with no deletion at 
19q13) were similar to the matched mucosa (Figure 50A). 
 
No miRNA gene resided in this 32 kb region. However, the region was inundated with 
several strong enhancers, repressors and insulators (Figure 48D). Segmental 
duplication event was also observed in this deleted region (Figure 48D). The presence 
of duplicated sequences can trigger the recombination machinery to initiate a crossover 
event indicating that this is a recombination hot spot. Thus, the deletion was predicted 
to disrupt chromatin architecture and consequently altered the regulation of 
neighbouring genes (Phillips-Cremins et al., 2013). This cis-regulation was specific as 
only the expression of MIA and MIA-RAB4B, located 35 kb upstream of the deletion, 
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were up regulated in the polyps of 344 but consistently down-regulated in the polyps 
of 421 (Figure 51A and B).  
 
The expression of TGFβ1, on the other hand, was similarly down-regulated in the 
polyps of both 344 and 421, suggesting that the deletion did not affect TGFβ1 regulation 
in the colonic mucosa and that regulating element(s) for TGFβ1 expression resided 
outside of the deletion and was not affected by the chromatin repositioning (Figure 
50B). 
 
MIA has been shown to increase the invasiveness of cancer cells not only in melanomas 
but also in solid tumours such as pancreatic and gastric carcinomas (El Fitori et al., 
2005). Hence, MIA up regulation in the polyps of 344 was likely to lead to increased 
invasiveness in CRC (Figure 51A). Notably, the read-through lncRNA, MIA-RAB4B, 
was also up-regulated (Figure 51B). A recent study has proposed a novel mechanism 
whereby the high mobility group AT-hook 2 (HMG2A) transcript promotes non-small 
cell lung cancer progression by competing with transforming growth factor β receptor 
III (Tgfbr3) for let-7 binding (Kumar et al., 2014).  
 
Since MIA-RAB4B and RAB4B share the same seed recognition site of miR-24, the 
similar mechanism was interrogated in this instance i.e. increased expression of MIA-
RAB4B could compete with the binding of miR-24 to RAB4B, thus reducing its 
degradation. This de-repression could conceivably be extended to other targets of miR-
24. The expression of other target oncogenes of miR-24 were investigated as the 
expression of RAB4B cannot be studied directly since unique primers targeting RAB4B 
could not be designed.  
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The expression of PIM2 and TAOK1 were up-regulated in the polyps of 344 but not in 
421 (Figure 52A and B). The expression of MAPK7 in the polyps of both 344 and 421, 
however, were similarly down-regulated compared to their matched mucosa (Figure 
52C). Thus, in contrast to MAPK7, the co-ordinately over-expression of MIA-RAB4B, 
PIM2 and TAOK1 suggested that the latter two oncogenes could be critical targets of 
MIA-RAB4B ceRNA. The over-expression of PIM2 and TAOK1 oncogenes in 344 but 
not 421 polyps implies that the dysregulation of these genes and consequently their 
participatory pathways could possibly mimic the dysregulation due to loss of APC. 
 
The main limitation of the study is the lack of samples from other family members of 
344 and 447 to show co-segregation of the disease with the 32 kb genomic deletion. 
Furthermore, no polyps were available from the second affected sibling 447 for the 
expression studies. Nevertheless, the expression of the various genes studied in the 
polyps of another APC mutation-positive patient, 424 (Figure 53), closely resembles 
that of 421, indicating that the expression of these genes were consistent for patients 
with different APC germline mutations and distinct from that of the patient with the 






Figure 53: RQ of (A) MIA, (B) MIA-RAB4B, (C) PIM2 and (D) TOAK1 transcripts 
in the polyps with respect to matched mucosa of 424. Axis Y, Relative 
quantitation (RQ); Axis X, samples 
 
Patient 421 has a novel APC codon 1309 deletion while patient 424 has whole APC 
gene deletion. Furthermore, there was a second somatic deletion in the wildtype allele 
consistent with this locus being important for polyp development. Thus, although it is 
conceivable that the causative gene may still remain to be discovered, the 32 kb 
genomic deletion contributed to the FAP-like phenotype in these APC mutation-
negative patients via both genetic and epigenetic mechanisms (manuscript in 







Figure 54: Flow chart summarizing the overall results for APC mutation-negative 












1. Combined LOH, CN and AsCN analysis uncovered five deleted regions in 
two affected siblings diagnosed as APC-mutation negative familial CRC 
patients. 
2. Long-range PCR confirmed a 32kb deletion on chromosome 19q13 in this 
family and loss of this wildtype allele were further observed in the polyps of 
the proband. 
3. The 32kb deleted region harboured CYP2A7 gene and was enriched with 
enhancer, repressor and insulator sites. 
4. Expression of MIA and MIA-RAB4B located 35kb upstream of the deletion 
were up-regulated in the polyps compared to the matched-mucosa of the 
proband. 
5. PIM2 and TAOK1, two target oncogenes of miR-24, were co-ordinately up-
regulated with MIA-RAB4B in the polyps, suggesting that MIA-RAB4B could 
function as competitive endogenous RNA to titrate miR-24 away from its 
targets. 
6. It is proposed that the 32kb deletion on chr19q13 disrupted chromatin 
organization leading to altered expression of several genes and lncRNA 
contributing to colorectal tumorigenesis via genetic and epigenetic 
mechanisms.    
  
 155 
Chapter 9 Overall Conclusions and Future Study 
 
We performed a GWAS on 1,000 stringently defined CRC cases from SGH and 1,000 
age-, gender- and ethnicity-matched healthy controls from the SCHS using the 
Affymetrix Genome-Wide Human SNP6 platform to identify risk loci for sporadic 
CRC in SCH. Using this GWAS dataset, we replicated several CEU-identified risk 
variants (Thean et al., 2012). Even though we did not identify any new SNP variant in 
SCH that were validated in an independent replication panel at genome-wide 
significance, our dataset contributed to the identification of a new SMAD7 risk variant 
in East Asians by pooling summarized allele frequencies from our GWAS dataset with 
that of the Asia Colorectal Cancer Consortium (Zhang et al., 2014b). Moreover, 
combining the rs5275 frequencies from our CRC imputed dataset with that from our 
collaborators (at the National Cancer Centre Singapore) enabled a significant 
association to be found for CRC risk in Singapore female patients (manuscript in 
preparation).  
 
We succeeded in identifying a rare CNV at chr14q11 encompassing CHD8 and two 
common CNVs at chr3q13.12 encompassing CD47 and chr12p12.3 consisting RERG 
and ARHGDIB significantly associated with sporadic CRC in SCH using the GWAS 
dataset (manuscript in preparation). The Odds ratio for the rare CNV (OR=1.92, 95% 
CI 1.59-2.3) especially is considerably higher than those obtained from the SNP risk 
loci (typically ≤ 1.2) reported thus far. To our knowledge, this is the first rare CNV that 
is validated to be associated with sporadic CRC risk. 
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There could be several reasons why the SNP association test in this study did not 
identify any new risk variant contributing to sporadic CRC. First, the sample size could 
be too small and hence the genetic power is low. Since our cases are sporadic with no 
family history, we would require a much larger sample size. Based on the genetic power 
calculation (Gusev et al., 2014b), if the genotypic relative risk is at 1.2, and associated 
power at alpha=0.05, the number of additional samples needed for 80% power was 
calculated to be around 1,300 for both cases and controls with case:control ratio at 1:1. 
This implies that another 2,600 samples are required. However, genetic power 
calculation is based on prediction and may not reflect the true situation. By introducing 
confounding factors unintentionally during experiment, the detection power might be 
even lower compared to the prediction. Thus, even more samples are required. 
Nevertheless, the current sample size is sufficient for CN analysis which indicates that 
structural variant interrogation algorithm is probably more robust. 
 
Second, the healthy controls in the GWAS panel are from the SCHS and these are 
population controls recruited from public housing i.e. Housing Development Board 
(HDB) dwellers while the controls for the replication panel were recruited from the 
Health Screening Unit at the SGH and hence were hospital controls which tend to be a 
more well-informed and health-conscious sub-group of the population. To what extent 
these two control panels differed is not known but earlier studies have alluded to 
differences in population vs hospital recruited controls (Maurano et al., 2012). In this 
study, even with imputation of the CRC GWAS dataset which increased the density of 
the SNPs substantially, we did not manage to replicate the 5 candidate regions in the 
RP although all contained interesting candidate loci. 
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Third, there are software and algorithm limitations to contend with. For instance, the 
genotyping algorithm for SNP clustering could be improved. We did not replicate the 
5 candidate regions from haplotype-based analysis because one of the SNPs included 
in the haplotype block always clustered badly thus yielding false positive association.   
 
In the future, using a case-specific GWAS design to interrogate the role of risk variant 
in disease subgroup, for example, germline variants that contribute to metastasis, may 
give a more promising outcome. A study has showed that a disease subgroup that 
consists of more homogeneous cases have relatively higher power and the effect is even 
stronger for rare variants detection compared to a heterogeneous group with higher 
sample size but relatively low genotypic risk (Traylor et al., 2015). Genetic power 
improved drastically for subgroup analyses, particularly for genetic relative risk <1.15. 
This suggests that GWAS based on case subgroups could be a more powerful strategy 
to uncover the missing heritability in CRC (Traylor et al., 2015).      
 
The role of CNVs especially the rare CNV will be investigated further. More replication 
panels in other populations or disease sub-groups such as early onset CRCs will be 
explored. The role of CNL affecting the downstream genes and pathways will be further 
elucidated with eQTL studies in more samples. eQTLs contain DNA variants that 
influence expression pattern of genes. Although most of the GWAS identified loci are 
located in desert regions or non-coding regions, these regions contain regulatory 
elements that are able to effect genes in the vicinity (Maurano et al., 2012; Gusev et al., 
2014a). Hence, eQTL studies will be able to provide the important information between 
DNA variants and the effected biological mechanisms.  
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In addition, collaboration with other consortiums, e.g. the Asia Colorectal Cancer 
Consortium, will help tremendously in exploiting the GWAS data to its full potential. 
Development of GWAS consortia has contributed to impressive numbers of discoveries 
as well as replications of disease risk variants. Collaboration will be a necessity to 
enable massive data sharing.  
 
Overall, sample size was the major limitation, be it the GWAS study for sporadic CRC 
as well as the familial CRC family. Other limitations as mentioned at the end of each 
chapter include experimental design, software limitations and technical issues that 
could be improved. The invaluable experience gained from this study will serve as the 
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